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Editorial
Neurology is one of the oldest yet most enigmatic
fields of medicine. The reasons for this are many and
this issue of the UWOMJ highlights just a few common
explanations.
The first is that the
function of the brain is nearly
impossible to separate from the
impacts of its functions. That is,
neurological function produces
thoughts and behaviours that
serve to build communication,
relationships, and culture. In this
way, neurology cannot be viewed
without consideration of psychology, psychiatry, even anthropology.
While neurology is not
unique in that its function and subsequent dysfunction have implications outside of medicine, it is the
extent of this enmeshing that makes neurology
particularly fascinating. Naylor, Kudlow and Shu
explore this theme in their examination of physical
activity on cognitive functioning, and Wang, Suppiah,
Jiang, Bahreini and Rhee question the role of sleep in
memory consolidation.
A second contributor to the complexity of
neurology is the disconnect between structure and
function. Consider the heart: its function can be
inferred by a careful examination of the valves, the
vessels, and the layers of the walls. Analogies have
been drawn to plumbing and engineering to help
explain the function of the heart. In contrast, the
brain affords no such luxury. The structure of the
brain offers few clues as to its function. Instead,
scientists and clinicians have relied on dysfunction in
order to explain function. It is through understanding
disease that we have come to appreciate the normal
function of the brain.
As an historical example, the function of the
recurrent laryngeal nerve was discovered when
Galen’s scalpel slipped during an experiment on a pig.1
The animal survived the operation, but no longer
squealed like his cohort. History could have taken a
few roads from here; Galen could have abandoned
medicine, chastising himself for suboptimal surgical
technique. Instead he asked why the pig no longer
squealed. In this case, it was not a meticulously
crafted experiment that led to discovery, but keen

observation and an inquisitive nature.
As Galen found, nature can present data
without a structured laboratory environment. This is
not to say that neurological discoveries are accidents; it requires someone
to notice the phenomenon and probe
deeper. The next step is to seek out
similar cases, which makes the
scientific literature so important. In
the grading of evidence, case reports
are often viewed as inferior to
randomized controlled trials. But
sometimes, as Galen found, one case
can spark discovery. For this reason,
the UWOMJ prides itself on featuring
case reports. For instance, Hamidi
describes a case of aggressive behaviour that was
ultimately attributed to a brain tumour.
The UWOMJ is grateful to the numerous
individuals who contributed to this issue, including
our editors, feature writers, advisory board, faculty
reviewers, and advertisers.
With your ongoing
support, we will continue to produce issues that will
hopefully inspire, inform, and reignite your passion
for medicine.

Laura Hinz
Senior Associate Editor
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Clinical procedures
Interventional neuroradiology and the treatment of carotid artery stenosis
and intracranial aneurysms
Sandeep Dhaliwal (Meds 2013) and Edward S. Weiss (Meds 2012)
Faculty reviewer: Dr. Andrew Leung, Department of Radiology, UWO
Introduction
Cerebrovascular diseases are the third leading cause of
mortality in Canada and the United States.1,2 Recent advances in the field of endovascular surgical (interventional)
neuroradiology have enabled the treatment of these
conditions using minimally invasive catheter-based technology assisted by radiologic imaging. Boasting a reduction in
recovery time and associated pain, these procedures are
increasingly being utilized as an alternative to traditional
surgical intervention.
When applied in clinical practice, neuroendovascular
interventional therapies are primarily used in one of two
possible forms: 1) revascularization leading to reopening of
blood vessels as used to treat acute ischemic stroke, arterial
stenosis, and dural venous thrombosis; and 2) embolization
leading to the occlusion of blood vessels as used in the
treatment of aneurysms, arteriovenous malformations, and
vascular tumors. Utilizing this distinction, an exploration of
the most common neurological conditions treated by
interventional neuroradiologists – carotid artery stenosis
and intracranial aneurysms – will be undertaken.
Origins of interventional neuroradiology
Historically, the roots of interventional neuroradiology can
be traced back to the late 1920s, when Egas Moniz used
iodides to visualize the cerebral vasculature on radiographs.3 Several years later, the first attempt at catheterization was successfully completed by Werner Forssmann
when he placed a urinary catheter into his own antecubital
vein and advanced it into his heart.4 In 1960, Luessenhop
and Velasquez demonstrated that intracranial vessels could
be catheterized,5 and by 1974, these advances had opened
the door for Serbinenko to use flow-directed balloon tipped
catheters for the treatment of intracranial aneurysms – the
first time an endovascular approach was utilized for the
treatment of a cerebrovascular disorder.6 In Canada, the
pioneering work in this field was conducted at University
Hospital in London, Ontario where Drs. Gerard Debrun,
Fernando Viñuela, and Allan Fox established a neuroendovascular centre to test and clinically apply Serbinenko’s
methods.7
Today, the basic principle of all neuroendovascular
procedures involves percutaneous entry, usually through
the femoral artery, although the brachial and radial arteries
are also possibilities. In 1953, a Swedish radiologist, SvenIvar Seldinger, introduced the procedure that is now
commonly employed to obtain vascular entry by all vascular
interventional disciplines.8 Figure 1 illustrates a modern
approach to the Seldinger technique whereby the vessel of

Figure 1. Illustration of a modified Seldinger technique of
arterial access through trocar cannulation, guidewire and sheath
insertion, and cathether introduction.
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interest is commonly punctured by a trocar (hollow needle),
and a guidewire is inserted through the needle. The
guidewire is used to introduce a catheter (or sheath) which
can be used to deliver an array of items to the target lesion.
As such, guide catheters can be directed into the supraaortic vessel of interest to allow for the highly selective
delivery of coils, embolic materials, and even drugs into
regions of interest.9 Seldinger showed that his technique
could be used to access all arteries in the body via the
femoral route,10 and the current practice of using ultrasound
to aid in vessel localization has raised its safety profile.
Revascularization: carotid artery stenting
The application of endovascular techniques is routinely
used for the treatment of atherosclerotic disease involving
the extracranial carotid, vertebral, subclavian and brachiocephalic arteries. Initially treated using balloon angioplasty,
interventional techniques have now progressed to the use of
stent-supported angioplasty. As such, this approach is
currently offered as a therapeutic alternative to traditional
methods of open surgery for patients who have failed
maximal medical therapy, or those who present as poor
surgical candidates. Although there are numerous cerebrovascular conditions for which revascularization is
possible, its use in treating carotid artery stenosis remains
by far the most frequent occurrence.11
Carotid artery stenting (CAS) is typically performed
under conscious sedation using local anaesthetic to enable
neurologic monitoring of the patient during the procedure.12
Following puncture of the femoral artery, selective catheterization of the common carotid artery is achieved. Prior to
proceeding, preliminary diagnostic angiography of the
carotid bifurcation is done in a minimum of two planes to
provide the operator with information about the anatomy of
the patient. Anatomical considerations form the basis for
choosing between various sizes and shapes of catheters. For
example, in older patients, vessel elongation, tortuosity and
dilation can necessitate the use of larger-diameter and
hence stiffer catheters in conjunction with stiffer
guidewires.13 Patients are intravenously infused with
heparin, and once the operator has determined the appropriate interventional strategy, the guide wire is used to
cross the stenosed segment. The stent is then deployed and
correctly positioned under fluoroscopic control.
Named after an English dentist who invented the
device in the late 19th century, stents are metallic structures
designed to maintain vessel patency. Self-expanding and
balloon-expandable stents are available for use, and these
devices are either composed of a thermal expansion alloy
(nitinol) or stainless steel. Although numerous designs exist,
stent selection does not appear to influence patient outcome.12 Nonetheless, there are several drawbacks regarding
the use of stents in treating cerebrovascular disease. Firstly,
stent placement can initiate a robust cellular response,
resulting in intimal hyperplasia that can cause restenosis of
the affected area. The overall restenosis rate (>50%
decrease in vessel diameter) one year following CAS has

been reported to be as high as 20.8% in some trials.14
Additionally, stents are highly thrombogenic and patients
are recommended to undergo several days of preoperative
treatment with aspirin and clopidogrel. Not surprisingly,
experimental evidence suggests oral aspirin (325 mg/day)
and clopidogrel (75 mg/day) display a synergistic effect on
platelet aggregation inhibition, antithrombotic activity, as
well as preventing restenosis.15,16 Finally, the risk of embolization caused by procedural manipulation poses a significant risk to the patient. MRI studies suggest that upwards of
15 percent of patients develop new ischemic lesions in the
brain following interventional stenting of CAS, although half
are asymptomatic.17 To reduce the microembolic burden
associated with stenting, embolic protection devices (EPDs)
are increasingly being used. Currently, two types of cerebral
protection strategies can be employed: 1) distal protection
in the form of an occlusion balloon or filter; or 2) proximal
protection in the form of flow interruption or reversal
devices.18
Embolization: intracranial aneurysms
An aneurysm is a dilation of a vascular structure and is
particularly troublesome when it occurs in the cerebral
circulation, as rupture can often cause catastrophic loss of
neurologic function and death. The larger arteries at the
base of the brain are predominantly affected, likely due to
their unique morphology – thinner walls, lack of external
elastic lamina, and lack of surrounding supporting tissue.19
Traditionally, surgical obliteration of aneurysms has been
the gold standard treatment, while endovascular intervention was typically reserved for patients who are medically
unsuitable for surgery or for those who refuse open surgery.
For example, the location of some aneurysms, such as the
intracavernous carotid artery and basilar apex, dictated a
preference for endovascular intervention if possible.9
Today, the majority of aneurysms are treated using coils.
Embolization is typically carried out with the patient
under general anaesthesia, and arterial access is achieved as
outlined above for CAS. Numerous strategies exist for the
endovascular treatment of intracranial aneurysms depending on the nature of the lesion. Commonly, aneurysmal
occlusion is achieved by the use of the Guglielmi Detachable
Coil system (GDCs).20 The aneurysmal sac is densely packed
with coils until no further angiographic filling is seen.
Approved for use in 1995, GDCs are electrolytically detachable platinum coils that offer the operator the advantage of
being able to withdraw coils from the aneurysm and
reposition them if the initial result is less than satisfactory.
Alternatively, stents can be used as a scaffold to support
detachable coils, particularly in the case of wide-necked
aneurysms, as shown in Figure 2. In this scenario, a stent is
deployed across the neck of the aneurysm, and the coils are
delivered into the aneurysmal lumen via a microcatheter
passed through the stent interstices. Occasionally the size
and shape of the aneurysm precludes it from being embolized by coils or surgically clipped, and therefore balloon
occlusion of the parent artery is undertaken to stop all
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Figure 2. Stent serving as scaffold to support detachable coils in treatment of a
wide-necked aneurysm. (Used with permission.)

blood flow to the aneurysm.21

5.

Conclusion

6.

The past decade has seen an explosion of minimallyinvasive procedures undertaken to treat various cerebrovascular conditions. Currently, randomized trials
evaluating the benefits of endovascular treatments are
ongoing. As technological advances are made, the safety and
efficacy of these procedures are expected to improve. In
this manner, techniques employed by interventional
neuroradiologists offer a promising alternative to current
therapeutic paradigms.

7.

8.

9.
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Alzheimer’s disease: a review of diagnostic criteria
Jai Prashanth Jayakar (Meds 2013) and Julie Huang (Meds 2012)
Faculty reviewer: Dr. Christopher Brymer, Division of Geriatric Medicine, UWO
Introduction
Dementia is a syndrome in which affected individuals have
impairment of memory and at least one other cognitive
area, for example, orientation or comprehension.1 The
diagnosis of dementia corresponds to a variety of etiological
domains, from cerebrovascular disease to neurodegenerative disease. However, Alzheimer’s Disease (AD), which is a
neurodegenerative disease of uncertain origin and pathogenesis, is the most common form of dementia in the
elderly.2
First described by Alois Alzheimer in 1906, AD is a
currently incurable neurodegenerative disease that primarily affects adults. Estimated to affect over 4 million Americans, AD places a heavy burden on the healthcare system.1 It
is very unusual for this disease to occur in individuals less
than 60 years of age, and it is reported to have a slight
predilection towards affecting women rather than men.3
Early AD typically presents with an insidious onset of mild
cognitive impairment, often in the form of short term
amnesia, which may be confused with the effects of aging or
stress.3 This is followed by progressive functional and
cognitive impairment in multiple domains, with some
studies reporting that the mean survival post AD diagnosis
is around 3-8 years,4 depending on factors such as the
severity of cognitive impairment and functional deterioration.5 In later stages, AD can manifest with non-cognitive
neurological symptoms, such as myoclonus and seizures.
The progress of AD clinically is often measured by mental
status scales such as the Mini-Mental State Examination
(MMSE) and the Clinical Dementia Rating Scale.3 However,
these scales have their own limitations in terms of corresponding with the rate of clinical decline.
Currently, the only definitive way to secure a
diagnosis of AD is through histopathological examination of
brain tissue.3 However, this is neither feasible nor is it
practised clinically except for confirmation of diagnosis at
autopsy. Rather, the mainstays for establishing a working
diagnosis of AD are clinical assessment criteria. In this
paper, we explore these tools and discuss their shortcomings in AD diagnosis. We also review some of tests that are
useful in differentiating AD dementia from other major
types of dementia.

Clinical criteria for a diagnosis of Alzheimer’s Disease
While a number of diagnostic criteria for AD based on
clinical grounds have been proposed, two major sets of
clinical criteria are used in North America to reach a
working diagnosis of AD. Both these criteria take into
account some well established features of AD, such as the

history of insidious onset and progressive course of deterioration, as well as evidence of cognitive impairment in
multiple areas.3 Conducting a detailed cognitive and general
neurological examination and evaluating the level of
cognitive impairment and dementia using the MMSE
provide the essential clinical information to which these
criteria may be applied.
NINCDS-ADRDA criteria
In 1984, a task force established by the National Institute of
Neurological and Communicative Disorders and Stroke and
the Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) put forth a set of clinical criteria for
diagnosis of probable AD.6 These are provided in Table 1.
Additionally, the criteria put forth by the same group for
possible AD, where the degree of suspicion is lower than
with probable AD, are also provided in Table 1.

Probable Criteria

•

•
•
•
•
•

Dementia
established
by
clinical
examination and standardized brief mental
status examination and confirmed by
neuropsychological tests
Deficits in two or more areas of cognition
Progressive worsening of memory and
other cognitive function
No disturbance of consciousness
Onset between 40 and 90 years
Absence of other systemic or neurologic
disorder sufficient to account for the
progressive cognitive defects

Possible Criteria

•
•

•

Atypical onset, presentation, or progression
of dementia without known etiology
Presence of another potentially causative
systemic or neurologic disorder that is not
thought to be the etiology of dementia in
this case
Progressive deterioration in a single cognitive domain in the absence of any other
etiology

Table 1. NINCDS-ADRDA criteria for diagnosis of AD.
Adapted from Feldman et al.3
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The validity and reliability of these criteria have been
investigated by a number of studies, with some yielding
optimistic conclusions. For example, one study showed that
diagnoses of AD made based on these criteria are confirmed
by autopsy in 87% of cases.7 A study by the National
Institute of Mental Health Genetics Initiative found these
criteria to have good reliability and validity, with a diagnostic sensitivity of 80%.8 However, some criticisms of these
criteria have also been made. For example, one study
showed that the interrater reliability for AD diagnosis using
these criteria was only low to moderate.9 Another study
showed that these criteria were not effective in distinguishing frontotemporal dementia from AD dementia in a group
of 56 patients.10 This lack of specificity has been attributed
to be a result of inadequate emphasis of the saliency of the
amnesia component of AD.3 Furthermore, since the NINCDSADRDA criteria are fairly old, they may not reflect recently
discovered biomarkers and genetic findings that can help
support an AD diagnosis.

making a diagnosis. However, in a study of 200 patients that
compared the NINCDS-ADRDA criteria and the then-current
DSM criteria (DSM III-R) against the gold standard of
histopathological examination, the NINCDS-ADRDA probable and possible criteria together were found to be 61%
specific, 96% sensitive, and 85% accurate in detecting AD
while the DSM criteria were found to be 51% sensitive, 96%
specific, and 66% accurate in detecting AD.12 Another study
showed that the interrater reliability between the NINCDSADRDA and the DSM-III criteria are comparable,13 and an
evidence-based review written by the American Academy of
Neurology (AAN) in 1994 concluded that both sets of
criteria for AD diagnosis were sufficiently reliable and valid
and that they should be used.14 More recent evidence
indicates that documenting an objective progression of
cognitive decline over a 12-18 month period is both highly
specific and sensitive for AD,3 however, this is logistically
hard to execute.
Excluding other causes of dementia

DSM-IV-TR criteria
The other commonly used clinical criteria for AD diagnosis
are derived from the current version of the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV-TR) published by the American Psychiatric Association.11 These
criteria are provided in table 2.

1.

The development of multiple cognitive
deficits manifested by both:
· Memory impairment
· One or more of the following cognitive
disturbances: aphasia, apraxia, agnosia,
disturbance in executive functioning.

2.

The cognitive deficits cause significant
impairment in social or occupational functioning and represent a significant decline
from a previous level of functioning.

3.

The course is characterized by gradual
onset and continuing decline.

4.

The deficits are not due to another brain,
systemic, or psychiatric condition.

5.

The deficits do not occur exclusively
during the course of delirium.

Table 1. DSM-IV-TR criteria for diagnosis of AD.
Adapted from Feldman et al.3

One argument in favour of the DSM-IV-TR criteria is that
they do not necessitate neuropsychological testing in

As mentioned earlier, dementia can be present in a wide
variety of neurological disease entities. Excluding depression is an important part of diagnosing dementia. Depression is more common in old age than dementia, and is
treatable. Chronic pain and medication side effects can also
be confused with dementia, therefore, clinical assessments
need to be thorough in order to delineate these other nonAD causes of cognitive decline.
Laboratory and imaging technologies can also be
helpful in ruling out non-AD diagnoses of dementia. For
example, according to guidelines issued by the AAN, brain
imaging, preferably MRI, is indicated in those patients with
suspected AD.14 This is important because imaging can
reveal structural problems (e.g. hematomas), brain atrophy,
and cerebrovascular disease, which can all present similarly
to AD. Specific imaging features for AD diagnosis have not
been firmly established, though some studies have reported
reduced hippocampal volume to be correlated with AD.15,16
However, there is also evidence that AD and aging exhibit
substantially overlapping atrophy patterns in the hippocampus and entorhinalcortex, so age-specific criteria are
required.17 Special imaging techniques (e.g. fluorodeoxyglucose-positron emission tomography) have been developed
that can highlight areas of hypoperfusion in AD or that can
reveal imaging features that distinguish AD from other
diseases causing brain atrophy.18 However, these techniques
need to be evaluated further for their ability to provide
information that affects therapeutic decision making;
distinguishing between clinical entities whose treatment is
the same does not help. They are also not universally
available, and they are not routinely used for AD at present.
Laboratory tests are useful in ruling out other
factors that can contribute to dementia. For example, B12
deficiency, which affects homocysteine and methylmalonylCoA metabolism, is associated with irreversible neurological
damage.19 Hypothyroidism can also contribute to a dementia-like presentation, therefore screening for B12 deficiency
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6.
7.

8.

9.

10.

11.

Conclusion
In this paper, we have reviewed some major clinical criteria
that are used in making a provisional diagnosis of AD and
reported on the literature evaluating the credibility of these
criteria. While the NINCDS-ADRDA guidelines have been
used for a long time and have been shown to have reasonable validity and reliability, they are lacking in specificity,
and need to be updated to incorporate the latest advances in
diagnostic technology. Studies have found the DSM-III-R
criteria to be comparable to the NINCDS-ADRDA diagnostic
criteria, however, there is a clear dearth of research in
evaluating the value of the DSM-IV-TR criteria for AD. In
addition to these clinical criteria, other tests such as
neurological imaging and serum B12 tests, can be valuable
in excluding non-AD differential diagnoses of dementia.
Given that the DSM-V is slated for publication in 2012, we
hope that the AD criteria published therein will incorporate
the merits of existing criteria with additional criteria that
reflect our expansion of diagnostic knowledge and tools in
this area.

12.

13.
14.

15.

16.
17.
18.
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Diagnostic review

and hypothyroidism is important. However, clinicians
should not order multiple laboratory tests unnecessarily:
some studies show that this is not a cost-effective process,
owing to the relative rarity of a treatable metabolic cause of
dementia.20 Given the right clinical picture (e.g. a patient
with chronic alcoholism, in whom B12 deficiency is likely),
laboratory tests are warranted. A number of studies have
revealed that serum or CSF levels of a beta-amyloid peptide
(called Aβ 42), which is suspected to play a role in AD
pathogenesis, may be predictive for AD in patients with mild
cognitive impairment, but these measurements have not
been formally included in clinical practice guidelines yet.21
Genetic testing does not have a routine role in AD diagnosis,
but some evidence suggests that testing for presenilin-1
mutations may be considered on a case-by-case basis in
unusual presentations of disease, for example in young
patients with a strong family history, when appropriate
genetic counselling is provided.22
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Should physicians be taking cognitive-enhancing drugs?
Hang Shi (Meds 2013)
Faculty reviewer: Dr. Lois Champion, Departments of Critical Care and Anesthesia, UWO
With the advent of the pharmacological age, a brave new
world where the neurological enhancement of the human
mind through chemical substances is no longer confined to
the realm of science fiction. Variously described as cognitive
enhancing drugs, smart drugs, or nootropics, there is an
ever-growing list of drugs on the market that can improve
mental function such as memory, attention, motivation, and
concentration.1 While initially researched for the therapeutic treatment of psychiatric disorders such as Alzheimer’s
and Attention-Deficit Hyperactivity Disorder (ADHD), there
is increasing evidence that various stimulants and antidepressants are being used off-label for the enhancement of
mental performance in healthy individuals.2
The controversial use of these drugs by university
students and the military has been well documented in the
literature.2 However, physicians have not been a focus in the
discussion despite being a susceptible demographic group
with predisposing risk factors. The high levels of stress,
fatigue, and pressure especially prevalent among residents
and certain shift work specialties, such as emergency
medicine,3-5 may make the use of these cognitive-enhancers
appealing. As a result, a candid discussion of the ethical
implications is well warranted. This article examines the
relevant ethical arguments that are important in determining whether physicians should be taking cognitiveenhancing drugs.
The wisdom of repugnance: the “yuck” factor
While the use of neuro-altering drugs is widely deemed
morally acceptable as a medical intervention in neurological
disorders, the use of these same drugs in healthy individuals
often elicits guttural reactions.6,7 The use of amphetamines
for narcolepsy is not met with nearly the same outcry as its
use by ambitious university students to improve test scores.
Once the line crosses from treatment of disease to enhancement of normal function, a fundamental change in acceptability seems to occur. One explanation is that the process of
cognitive improvement through a pill is unnatural or
inauthentic.8 However, our use of other more common
chemical remedies to enhance cognition is not anything new
or fundamentally more “natural.” The widespread use of
caffeinated beverages is a form of cognitive-enhancement,9
but has not evoked public scrutiny or protest. Why should
the ethical considerations change depending on whether the
medium is in the form of a drink or pill?
Some arguments that call into question whether
there is anything intrinsically wrong with medicating to
enhance cognitive function may border on begging the
question, but nevertheless have their implications. If the
very principle of medicating the healthy is unethical, then
advocating for pharmacological enhancement within a

profession where public perception and patient trust is so
important may be imprudent.
Maximizing utility and the creation of SuperDocs
The use of cognitive enhancing drugs by physicians can
potentially improve the well-being of both physicians and
their patients. The well-documented high levels of fatigue,
sleep-deprivation, and stressful environments that physicians endure have been shown to lead to lowered vigilance
and an increase in medical errors.10 In a double-blind
placebo controlled study with sleep deprived emergency
physicians, the stimulant modafinil (Provigil®) was shown
to improve cognitive ability by improving sustained
attention as well as increasing cognitive control and
working memory.11 It is not a far stretch to consider how
more attentive, alert, and cognitively functioning physicians
can reduce medical errors, improve productivity, and have
the fortitude to be more patient-centred in their approach.
Not only would this benefit patients by improving their
health outcomes, it would benefit the physician by lowering
their levels of anxiety and stress, and may even benefit the
health care system by improving physician efficiency. If a
hypothetical ideal cognitive enhancer can augment desired
and predictable changes in mood, personality, attention, and
memory, society as a whole may be better off. From a
utilitarian point of view, the potential benefits of cognitively
enhanced physicians may be too great to ignore with everprogressing advances in pharmacological agents.
Primum non nocere
Therapeutic agents have inherent risks and the potential for
harm; the maxim of “first, do no harm” remains a fundamental principle of medicine and serves as a reminder of how
purported beneficial interventions often have unforeseen
and undesirable consequences. While psychotropic drugs
such as stimulants and anti-depressants are widely prescribed medications with few side effects,13 even minimal
risks need to be taken into account when used by healthy
individuals. While patients with severe symptomatic
neurological deficits may tolerate the risks involved, the
threshold of risk tolerance is significantly lower for healthy
individuals.14 In the study of the use of modafinil among
sleep-deprived physicians, the treatment group found it
more difficult to sleep when the opportunity arose.11 While
sleep-deprived physicians could use the drug to maintain
attention and cognitive function in the short term, the
resulting trade-off may lead to a Faustian bargain. Even
worse, the long term effects of these psychotropics are
largely unknown.15 The pendulum would certainly take a
devastating swing from benefit to harm if a generation of
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“But everyone else is doing it”
One of the most commonly cited issues with the use of
cognitive enhancing drugs by university students is its
perception as a form of cheating, and one could argue that
ambitious residents or physicians who take these cognitive
enhancers to “get ahead” violate the sanctity of fair competition on an even playing field.1 Although the field was never
strictly even to begin with due to socioeconomic, genetic,
and environmental determinants, improving productivity
through artificial pills may undermine the value of effort
and hard work.16 The issue especially becomes problematic
if there is an unequal distribution of use amongst different
physicians or different specialties. Should use only be
recommended for specialties with the highest levels of
fatigue, sleep deprivation, and stress? Should only those
physicians deemed most in need, namely those with the
worst attention and cognitive ability, be prescribed these
enhancers?
If there are no regulations in place, unintended and
indirect coercive forces may come into play where physicians who otherwise would not have taken these enhancers
now feel compelled to do so. If doctors who use the cognitive enhancing drugs achieve improved performance and
are perceived as superior by patients or colleagues, this puts
increased pressure on and makes it more difficult for those
who would otherwise opt out.1 Furthermore, with the
emphasis today on outcomes-based medicine and the
importance of hospital ratings on budgets, there may also be
external pressure from the employer or administration. In
the event that these drugs could approach a pharmacological ideal with maximum benefit and negligible harm, could
these cognitive enhancers become as compulsory as
scrubbing in to protect the safety of the patients?

practice, where the ‘quick fix’ is often the most attractive
strategy.1 Alternative solutions certainly exist, such as
optimizing shift schedules and improving work-life balance.
These strategies present less risk and address the root of
the problem: over-work, sleep-deprivation, and fatigue.19
However, as drug advances are made with improved
performance records and as better understanding of the
long-term effects become available, the reality is that a
growing number of people will practice neurocognitive
enhancement in the coming years. The sale of various
nutritional supplements that are purported to have cognitive-enhancing function have reached a billion dollars
annually in the United States alone, and market demand is
projected to rise.14 Given the easy accessibility of drugs to
physicians and compounded with their propensity to self
prescribe,17,20 the discussion concerning the guidelines and
regulations for the use of cognitive-enhancing drugs needs
to begin now.
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Introduction
Healthy behaviours learned early in life are more likely to
persist into adulthood. As such, there is a strong prima facie
case for health promotion interventions that target young
Canadians. That case is strengthened by the fact that risk
factors emerging early in life will take a cumulative toll and
could have debilitating consequences on future health.
One such risk factor is physical inactivity. Attention
in the past has tended to focus on the relationship of
inactivity among adults to increasing prevalence of risk
factors for chronic cardiovascular disease, viz. higher rates
of obesity, dyslipidemia, diabetes, and hypertension. Today,
however, there is growing interest in the long-term effects
of inactivity that commences in childhood. As summarized
below, physical inactivity is not only linked to the growing
epidemic of childhood obesity; contemporary evidence also
links higher activity levels to enhanced learning and raises
the possibility that exercise may be very important in
healthy cognitive development.

Academy of Paediatrics (AAP) recommends comprehensive,
preferably daily, physical education (PE) for children in
grades Kindergarten through 12.4 Despite this recommendation, only 3.8% of all elementary schools, 7.9% of all middle
schools, and 2.1% of all high schools in the United States
provide daily physical education for all students.5 Data from
Ontario high schools are also discouraging. Between 1999
and 2005, there was a significant linear decrease in the
percentage of students who were enrolled in PE: from
70.3% in 1999 to 60.3% in 2005.6
Adolescence may be a time of particular concern, as
academic pressures increase and many schools favour
classroom time over physical education. Indeed, one study
examining high school students in Ontario found a steady
decline in physical activity between 14 and 18 years of age.7
However, even pre-adolescents are not active enough. In
2002, approximately 82% of Canadian children aged 9 to 12
were not active enough to meet international guidelines for
normal growth and development.8
Gym in schools and academic performance

The childhood obesity epidemic
Obesity has become increasingly prevalent among Canadian
children and youth. Temporal trends can be appreciated by
defining a reference population and thresholds, e.g. overweight as body mass index (BMI) above the 85th percentile,
and obesity as BMI above the 95th percentile for a reference
population. Using 1981 weight distributions as a baseline or
reference group, one study of Canadian children aged 7–13
years found that the prevalence of overweight among boys
increased from 15% in 1981 to 35.4% in 1996 and among
girls from 15% to 29.2%.1 The prevalence of obesity in
children roughly tripled over that period, from 5% to 16.6%
for boys and 14.6% for girls.
Particularly in North America, physical inactivity is
one of the major causes of obesity. Increased caloric intake
is also important, but the two may well interact. For
example, Crespo et al. reported that US children who
watched 5 or more hours of television per day consumed on
average 175 kcal per day more than children watching not
more than 1 hour per day. 2 Both organized and unorganized sport and physical activities have been shown to reduce
the risk of being overweight by 10–24%, and of being obese
by 23–43%, after controlling for sex, family structure, and
socioeconomic status.3 In addition to effects on body fat,
cross-sectional studies have shown an association between
higher activity levels and increased bone mineral mass and
lower levels of tobacco and alcohol use in young people.4
Not surprisingly given the progressive increase in
childhood obesity, school-based physical activity rates are
alarmingly low amongst young people. The American

School-based physical activity interventions are seen as
desirable since students are a “captive audience” during
weekdays. There has been a presumption in some quarters,
however, that time spent outside of the classroom on
physical activity may decrease the academic performance of
pupils. Fortunately, several studies have shown that time
spent on physical education has no negative effects on
overall academic attainment.
In one study of 117 Australian primary schools, time
spent in physical education was not negatively related to
average school attainment in either literacy or numeracy.9
Similarly, a study from British Columbia found that a schoolbased intervention offering an additional 15 minutes of
physical activity a day did not reduce levels of academic
performance among students.9
Instead, the evidence
suggests that physical activity may enhance the academic
performance and cognitive functioning of young students.
One meta-analysis sought to aggregate the results of 44
studies pertaining to physical activity and cognition in
children, and found a significant positive relationship.8
Middle school students (grades 6-8) and elementary age
students showed the largest cognitive benefit from physical
activity. The type of activity was not a significant moderator
variable, suggesting that any type of physical activity had
beneficial effects.
Notwithstanding the results of the meta-analysis by
Sibley et al.,10 some newer evidence supports the notion that
different forms of physical activity may actually mediate
specific cognitive effects. One study examined the performance of 115 healthy adolescents aged 13-16 years on a test
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of attention and concentration. Students performed the test
after receiving either coordinative exercise, normal exercise, or a classroom lesson. Both the coordinative and
normal exercise groups showed enhanced test performance,
but coordinative exercise was the most effective. The
authors hypothesized that coordinative exercise might lead
to a ‘pre-activation’ of areas of the brain which also mediate
attention and other cognitive functions.11 As well, Coe et al.
suggest that intensity may also be a factor.12 They found
that students who performed vigorous activity had significantly higher grades than students who performed none,
while moderate physical activity did not affect grades.
Castelli et al. suggest that these effects accumulate
through an overall fitness effect, rather than being related
solely to recent exercise. 13 They examined 259 public
school students in third and fifth grades and found that
aerobic
capacity
was
positively
associated
with achievement, whereas BMI was inversely related.
Also relevant are the results of a systematic review
of 23 randomized controlled trials addressing exercise and
self-esteem. The review found that exercise has positive
short-term effects on self-esteem in children and young
adults.14 It has been hypothesized that improved self-esteem
may help to reduce or prevent psychological and behavioural problems in children this age group, which may
ultimately augment classroom performance.
Mechanisms for the neuropsychological effects of
exercise
These positive effects of exercise on learning in childhood
and adolescence are striking, and, encouragingly, appear to
be generalized to adult disorders. For example, increased
physical activity may delay the onset of Alzheimer disease, Huntington's disease and Parkinson's disease. There
is also some evidence to suggest that exercise mitigates the
pace of functional decline after neurodegeneration has
begun. Furthermore, while the mechanisms are not well
understood, exercise also seems to have both positive
effects on depression and anxiety, among other psychiatric
disorders.15
As sometimes happens, these empirical findings are
still not well-explained by the available basic science. One
line of evidence suggests that neurogenesis – i.e. the
production of new neurons – is important. Exercise clearly
stimulates neurogenesis in a portion of the hippocampus
that affects learning and memory.15 Since these new
neurons appear to have lower thresholds for activation,
neurogenesis could well underpin some of the positive
cognitive effects of exercise. In particular, Pereira et al.
showed that after 12 weeks of cardiovascular exercise
training, there was an increase in blood flow to the hippocampal region in rodents and humans. 16 This increase was
positively correlated with improved rates of learning a
hippocampus-dependent task. While a variety of growth
factors appear to play a role in mediating these blood flow
effects, no specific therapeutic role for those factors has
been elucidated thus far.

An alternative explanatory approach – less relevant
to children and youth – is to focus on the risk factors for
cognitive decline and delineate those that could be related
to physical activity. Among the risk factors for cognitive
decline are hypertension, hyperglycemia, insulin insensitivity and dyslipidemia, a cluster of features encompassed by
the ‘metabolic syndrome.’ Exercise reduces the impact of all
these risk factors. Thus, whether through direct central
neurological effects or through neuro-protective effects
mediated in part by mitigating cardiovascular risk factors, exercise seems likely to shape neurological development across the life course.15
Future directions
According to Canadian estimates for 2001, the economic
burden associated with physical inactivity was $5.3 billion.17
Thus, interventions targeting physical activity have the
potential to show large ‘returns on investment’. As already
argued, the logical place to start promoting physical activity
is childhood, in part to combat the epidemic of obesity
among children and youth. Indeed, we know that children
who are obese in their preschool years are more likely to be
obese in adolescence and adulthood and to develop diabetes, hypertension, hyperlipidemia, asthma, and sleep
apnea.18
Greater levels of physical activity among children
and youth may also lead to enhanced cognitive functioning.
However, much more can be done to elucidate mechanisms
and clearly delineate exercise modalities. Whereas human studies have emphasized frontal-brain-dependent
tasks (i.e. executive function), animal studies have focused
on hippocampus-dependent learning and plasticity. There
also remains a need for clarification as to which types of
exercise, and at what duration and intensity, will have the
optimal impacts on cognitive outcomes. Confounders
abound in observational studies; physical activity levels
may be associated with other mediating variables such as
socioeconomic status. Thus, to fine-tune the various
interventions, formal randomized trials are essential with
standardized outcome measures.
It seems defensible, however, to proceed sooner
rather than later with policy shifts that will promote
physical activity among children and youth. From a policy
standpoint, we applaud Ontario’s Healthy Schools program.
It was announced in 2005 that every Ontario elementary
student will take part in a minimum of 20 minutes of daily
physical activity. This initiative aimed to complement
existing physical education classes that occur twice or three
times a week for 30 to 40 minutes for elementary students.19 We would strongly encourage similar policies for
middle and high school students.
Last, we also encourage the development of a
rigorous agenda of basic, translational and applied research
that will clarify how best to promote physical activity across
the life course.

UWOMJ | 79:2 | Fall 2010
14

Cognitive impact of physical activity

1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

15.

Tremblay MS, Willms JD. Secular trends in the body
mass index of Canadian children. CMAJ 2000; 163
(11):1429-33.
Crespo CJ, Smit E, Troiano RP, Bartlett SJ, Macera CA,
Andersen RE. Television watching, energy intake,
and obesity in U.S. children: results from the Third
National Health and Nutrition Examination Survey,
1988-1994. Arch Pediatr Adolesc Med 2001;
155:360-5.
Tremblay MS, Willms JD. Is the Canadian childhood
obesity epidemic related to physical inactivity? Int J
Obes. 2003; 27: 1100–1105.
American Academy of Pediatrics: Physical Fitness
and Activity in Schools. Pediatrics 2000; 105(5):
1156-1157.
Kann L, Brener ND, Wechsler H. Overview and
summary: School Health Policies and Programs.
Study J Sch Health. 2007; 77: 385-397.
G Faulkner, J Goodman, E Adlaf, H Irving, K Allison, J
Dwyer. Participation in High School Physical
Education — Ontario, Canada, 1999–2005. MMWR
Morb Mortal Wkly Rep. 2007; 56(3).
Allison KR, Adlaf EM, Dwyer JM, Lysy DC, Hyacinth
MI. The Decline in Physical Activity Among Adolescent Students. Can J Public Health. 2007; 98 (2): 97100.
Ahamed Y, MacDonald H, Reed K, Naylor T, LiuAmbrose T, McKay H. School-Based Physical Activity
Does Not Compromise Children’s Academic Performance. Med. Sci. Sports Exerc. 2007; 39 (2): 371–376.
Dollman J, Boshoff K, Dodd G. The relationship
between curriculum time for physical education and
literacy and numeracy standards in South Australian
primary schools. European Physical Education
Review. 2006; 12 (2):151–163.
Sibley B, Etnier J. The Relationship Between Physical
Activity and Cognition in Children: A Meta-Analysis.
Pediatr Exerc Sci. 2003; 15: 243-256.
Budde H, Voelcker-Rehage C, Pietrabyk-Kendziorra
S, Ribeiro P, Tidow G. Acute coordinative exercise improves attentional performance in
adolescents. Neurosci Lett. 2008; 441(2): 219-23.
Coe DP, Pivarnik JM, Womack CJ, Reeves MJ, Malina
RM. Effect of physical education and activity levels
on academic achievement in children. Med. Sci.
Sports Exerc. 2006; 38(8):1515-9.
Castelli DM, Hillman CH, Buck SM, Erwin HE.
Physical fitness and academic achievement in thirdand fifth-grade students. J Sport Exerc Psychol.
2007; 29(2):239-52.
Ekeland E, Heian F, Hagen KB, Abbott JM, Nordheim
L. Exercise to improve self-esteem in children and
young people. Cochrane Database Syst Rev. 2004;
Issue
1.
Art.
No.:
CD003683.
DOI:
10.1002/14651858.CD003683.pub2
Cotman C, Berchtold NC, Christie L. Exercise builds

16.

17.

18.

19.

brain health: key roles of growth factor cascades and
inflammation. Trends Neurosci. 2007; 30 (9): 46472.
Pereira AC, Huddleston DE, Brickman AM, Sosunov
AA, Hen R, McKhann GM, Sloan R, Gage FH, Brown
TR, Small SA. An in vivo correlate of exerciseinduced neurogenesis in the adult dentate gyrus.
PNAS. 2007; 104 (13): 5638-5643.
Katzmarzyk PT, Janssen I. The economic costs
associated with physical inactivity and obesity in
Canada: an update. J. Appl. Physiol. 2004; 29: 90-115.
Hillman CH, Pontifex MB, Raine LB, Castelli DM, Hall
EE, Kramer AF. The effect of acute treadmill walking
on cognitive control and academic achievement in
preadolescent children. Neuroscience. 2009; 159
(3):1044-54.
Ontario Newsroom. 2005. Ministry of Education:
Healthy Schools Condition Healthy Minds. http://
ogov.newswire.ca/ontario/GPOE/2005/10/06/
c8547.html?lmatch=&lang=_e.html, retrieved May
2010.

Health promotion

References

UWOMJ | 79:2 | Fall 2010
15

History of medicine
Reflux, revolution, and the role of forgotten research in medical paradigms
Edward S. Weiss (Meds 2012)
Faculty reviewer: Dr. Paul Potter, Department of History of Medicine, UWO
Introduction

The case of peptic ulcers

The conventional view of science as a plodding, methodical
process free of entrenched interests and proceeding solely
on the basis of observable facts permeates popular thinking.
Scientists are often seen as seekers of truth, garbed all in
white, using their sheer brainpower to piece together the
innumerable parts of whatever grand puzzles capture their
respective imaginations. In truth, though, science often
progresses not only by evolution, but by revolution as well.
In his seminal work of scientific sociology, “The Structure of
Scientific Revolutions,”1Thomas Kuhn put forward the
notion of the paradigm shift as the major mechanism for
scientific change, and although the term has been popularized – almost to the point of losing its original meaning – it
still retains immense relevance for the analysis of current
events in the scientific and biomedical realms.
Kuhn posited that research into a particular scientific or medical problem takes place within the context of a
research programme, an overarching framework that
dictates the shape of the overall problem, as well as the
nature of the specific results needed to solve it. It is perhaps
best compared to a partially-solved jigsaw puzzle, in which
the dimensions of the puzzle are clear, and the shapes of the
missing pieces are discernible – one only has to find the
missing pieces that fit into particular spots to complete the
puzzle and construct a coherent image. However, sometimes one is left with puzzle pieces that don’t seem to fit
anywhere, and empty spots for which suitably-shaped
pieces cannot be found. In this case, one is forced to question whether the attempt at the puzzle is, indeed, correct, or
if perhaps the puzzle depicts something entirely different
and needs to be rebuilt from scratch.
Such is the case with science as well: data that pose
challenges to the dominant framework accumulate, and
important research questions go unanswered by the
research programme currently underway. A new theory is
put forward that accounts not only for the previously
established results, but also for the conflicting data that
troubled the dominant paradigm, and while the new
approach may not answer every remaining question, it does
provide a direction for further research to follow. However,
as will be demonstrated shortly, there is often considerable
opposition to the introduction of a new paradigm. Careers
and fortunes are often staked upon a widely-held paradigm,
and even though researchers may have the best of intentions, the words of Max Planck too often hold true: "a new
scientific truth does not triumph by convincing its opponents and making them see the light, but rather because its
opponents eventually die, and a new generation grows up
that is familiar with it."1

The classic example of a paradigm shift in medical thinking
relates to the etiology of peptic ulcers. Originally described
by Marcello Donati in 1586,2 gastric ulcers in particular
came to be attributed to the acid milieu of the stomach,
encapsulated in the famous proclamation of the Croatian
surgeon Karl Schwatz: “No acid, no ulcer.” Factors which
increased the amount of acid, such as stress and spicy food,
were naturally seen as contributing to the pathogenesis of
the dread disease. However, blaming acid alone for the
incidence of ulcers left several important facts unexplained.
For one thing, until the advent of effective antacid medication, the prescribed treatment was often ineffective. More
fundamentally, as early as 1875, it was proposed that
bacteria had a role to play in the development of peptic
ulcers, and in the late 1950s, it was recognized by some
clinicians that ulcers could be successfully treated with
antibiotics. The Greek physician John Lykoudis, for example,
discovered that his chronic ulcer problem went into
remission after he treated himself with antibiotics for a bout
of gastroenteritis. He later took out a patent on his antibiotic
ulcer preparation and attempted to publish an article in
JAMA, only to be summarily rejected.3 Lykoudis was
eventually fined 4,000 drachmas (about $900, accounting
for inflation) by the Greek medical disciplinary committee
for his unorthodox treatment,4 and the bacterial theory of
peptic ulcers resumed its usual lowly place in the dominant
paradigm until the work of Marshall and Warren in the
1980s finally set into motion the wheels of scientific
revolution and established that gastric infection with H.
pylori was a major cause of peptic ulcers.
What this paradigm shift serves to highlight is the
role of forgotten research, the undercurrent of data supporting alternate etiological factors that were never
incorporated into the dominant paradigm. That this
research is generally ignored – or censured, as in the case of
Lykoudis – is, in retrospect, difficult to justify scientifically,
but ultimately understandable. Before the attribution of
peptic ulcers to acid and acid alone, research in this area
was in what Kuhn called the pre-paradigm phase, in which
there is no consensus on a research programme, but the
research being conducted is nonetheless valid and scientific.
When the consensus of an acid etiology was reached,
research began operating in the second phase of Kuhn’s
hierarchy: normal science, in which experiments and
studies are conducted with the aim of filling in the missing
pieces of a defined puzzle. Concurrent with the ascendancy
of a particular paradigm is the frequent abandonment of
earlier, pre-paradigm directions in research, not because of
inherent invalidity, but because circumstances are such that
further exploration is unfeasible: researchers may change to
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Forgotten research in neurology
Neurology is certainly a field that has its share of unsolved
problems. The causative factors behind such diseases as
epilepsy, ALS, and Parkinson’s are still mostly unknown,
even if we have made progress towards understanding their
pathophysiology. Of all the theories currently circulating
that attempt to explain some aspect of neurological disease,
there is perhaps none as recently controversial and widelypublicized as the vascular theory of multiple sclerosis (MS),
which contests the widely-held notion that MS is predominantly an auto-immune phenomenon. While this author is
not in a position to comment on the ultimate validity of the
theory, or the degree to which it explains the phenomena it
claims to account for, an analysis of the issues surrounding
the theory and the potential it has for sparking revolutionary science is worth contemplating.
As was the case for peptic ulcer disease, there have
seemingly always been multiple theories accounting for the
pathogenesis of MS. As early as 1839, just a year after the
first recorded pathological description of multiple sclerotic
lesions, it was noticed that MS lesions appeared to involve
altered vasculature or hemodynamics, an observation that
was later made by Charcot himself.5 Intriguingly, an experimental study in dogs published in 1935 claimed that when
the cerebral veins were artificially obstructed, lesions
developed that were “so striking [in similarity to MS lesions]
that the conclusion appears almost inevitable that venular
obstruction is the essential immediate antecedent to the
formation of typical sclerotic plaques."6 The conclusion at
the time was that such obstructions were likely a result of
thrombosis, and as a result, treatment with anticoagulants

was attempted, with mixed results.7
In the years following the second World War, there
was increasing recognition that the inflammatory component of MS could be amenable to treatment. In 1969,
researchers carried out a placebo-controlled study of
adrenocorticotropic hormone (ACTH) in patients suffering
from exacerbations of MS, and found that it was an effective
symptomatic treatment.8 This paved the way for decades of
further research into pharmacotherapeutical initiatives
aimed at curbing the inflammatory process. The vascular
component was all but forgotten, and today, the majority of
drugs used to treat MS target the immune system, and
although they are often touted as breakthroughs, retrospective studies have shown that they have only modest effects
on established disease and somewhat questionable efficacy
in preventing disease progression.9,10
The modern attack on the dominant paradigm of MS
began in late 2008, when Paolo Zamboni and colleagues
showed that a particular set of extracranial venous anomalies were found in MS patients, but not in controls.11 (It
should be mentioned that Franz Schelling had attempted to
resurrect the vascular theory of MS in 1986,12 but his efforts
to secure funding for experimentation were frustrated, and
it was left to Zamboni to take the lead more than twenty
years later.) News spread quickly, and just a few months
later, patients were discussing the new findings and seeking
treatment for their venous stenoses and malformations at
centres all over the world. Internet forums were abuzz with
talk of a real breakthrough, as well as the personal anecdotes of those who had undergone treatment and found that
it had helped their symptoms improve. In late 2009,
Zamboni published the results of an open-label pilot study,
which showed that venous angioplasty reduced symptoms
and disability measures in those MS patients who had
demonstrated cerebrospinal venous insufficiency.13 Notably,
it should be pointed out that Zamboni does not argue that
MS is not an auto-immune disease, but rather that the insult
leading to inflammation and white matter lesions is often
vascular in nature, and likely a congenital malformation.14
Comparing the timeline of research into peptic
ulcers with that of MS, it appears that the two share a
similar trajectory. Both have their origins in a stage of preparadigm science prior to the twentieth century, an ascendant paradigm and a consequent programme of normal
science within the last hundred years, and a period of
potentially revolutionary science within the last few
decades. In both cases, researchers operating outside the
mainstream demonstrated findings compatible with older
theories that challenged the dominant paradigm, and in
both cases, their findings were met with skepticism. Lest we
forget, even Marshall’s dramatic demonstration of the
ulcerogenic properties of H. pylori (in 1984, he drank a
culture of the bacterium and subsequently fell ill with an
ulcer) was insufficient to convince the majority of clinicians;
eight years later, an informal survey showed that two-thirds
of gastroenterologists polled were still skeptical of the H.
pylori claim.15

History of medicine

a different field of study, there may not be sufficient
supporting knowledge or technological gadgetry to investigate a theory, or sources of funding may shift to approaches
that support the alternate, ascendant theory. When a
dominant paradigm is established and other theoretical
approaches are no longer en vogue, it is easy to all but forget
the historical context that gave rise to the current situation,
especially when the next generation of researchers comes
through the ranks having not even been informed of any
alternative theories to the dominant one.
Forgotten though they may be, alternate theories
and dusty old data often survive in some form or another. In
some cases, researchers outside the mainstream may
continue to investigate older approaches, earning the scorn
of their colleagues and collecting very little in the way of
grant money and prestige. Alternatively, a researcher may,
like John Lykoudis, discover quite accidentally through his
or her own personal experience, that the current paradigm
is lacking. Furthermore, an older theory may be resurrected
when contemporary researchers independently turn up
data that force them to dig through the literature for
theories that might explain their findings. Thus, forgotten
research has a vital role in maintaining one of the ultimate
principles of scientific enquiry – that current knowledge is
always subject to revision.
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Conclusions
As the debate over MS paradigms rages on, it is instructive
to analyze the situation at play and understand what it may
mean for medicine in general. Looking back on a century or
more of modern medicine, it is likely that at least some
answers to the pressing medical questions of our time have
already been found, but have been neglected amidst the
inevitable turmoil of shifting paradigms, ever-accumulating
data, and the cognitive dissonance stemming from overzealous adherence to a particular set of ideas. Luckily, advances
in technology and increasing access to more and more
sources of historical research data have provided us with a
rich reservoir of science to review and learn from. Whatever
the final outcome of the MS debate, it is a foregone conclusion that this will not be the last time forgotten research has
its last laugh.
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Addendum
A precursor to this article was originally presented to the
Harvey Club of London on April 20, 2010.
The author invites readers to submit further examples of
forgotten research at a new website created explicitly for
this purpose: www.forgottenresearch.com.
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Youth, adults and transitional patients with spina bifida: a multidisciplinary
approach to facilitating the passage from paediatric to adult care.
Ashley Kim (Meds 2013), Emma Farley (Meds 2013), and Allanah Li (Meds 2012)
Faculty reviewer: Dr. Adrianna Ranger, Department of Clinical Neurological Sciences, UWO
Children and adolescents with spina bifida – a unique
population
Spina bifida (SB), meaning “split spine” in Latin, is the most
common neural tube defect and the most severe congenital
disorder compatible with life.1 During the third to fourth
week of embryonic development, the central nervous
system begins as a neural plate and fuses into a neural tube.
SB is the failure of this neural tube to close and results in
three different categories of defects: occulta, meningocele
and myelomeningocele, the latter being the most severe and
the focus of this article. Fifty years ago, the prognosis of an
infant with myelomeningocele was grim as only ten percent
were expected to survive their first year.2 Today, survival
into adulthood exceeds 85% due to advances in the management of complications.1 While this is certainly a success in
neurosurgical medicine, deterioration in adulthood is
common in these survivors. One of the greatest challenges
remaining is the continuity of care between paediatric and
adult services, which requires a functional multidisciplinary
team.
Morbidity in the aging SB population is a complex
combination of physical, emotional and developmental
obstacles. The long term physical effects of SB include
muscle weakness or paralysis below the level of the lesion,
loss of sensation, and loss of bowel and bladder control.3
Following repair of the myelomeningocele, 70-80% of
infants develop some degree of hydrocephalus, which is
treated by implanting a shunt shortly after birth.4 If hydrocephalus is untreated, or if the shunt later malfunctions,
excess fluid may result in permanent brain injury, seizures,
or blindness. Unrecognized shunt malfunction is the leading
cause of death in adults with SB.4,5 This is a topic that adultcentered physicians must be educated in when caring for
patients with SB.
Concerning the emotional development of children
with SB, independent mobility is an important factor in
determining quality of life. The level of the lesion corresponds to prospective independent mobility. For lesions
above L2, loss of quadriceps and iliopsoas muscle function is
typical and wheel chair dependence is expected. 6 However,
lower lumbar and sacral lesions are usually compatible with
ambulation,7 for which early physiotherapy and orthopedics
consultations are crucial.8 Ambulation may mitigate the
decline in activity through adulthood resulting from obesity,
spinal and foot deformities including scoliosis and clubfoot,
and respiratory compromise. In a 2004 cohort study of 117
patients, 30% were ambulatory at 30 years follow-up, of
which 88% had lesions at L5 or below.9 This highlights the
importance of early intervention and appropriate rehabilitation in response to changes that occur over time.

Another important area of treatment for people
living with SB is the lifelong management of urinary
incontinence and impaired sexual function.10 Sexual
function may be reduced due to impaired neurological
innervation, or the psychological effects of negative selfimage and incontinence anxiety. However, there are two
common misconceptions that are held more by medical
students and doctors than by the young adults themselves:
that people with SB cannot be sexually active, and that they
cannot have babies.3 Both are untrue. Healthcare professionals should provide the proper education and counselling of safe sex and contraceptive services and should
address the increased risk of latex allergies. Family planning
services and pap smears should also be readily available to
patients with SB,3 and must be sensitive and specific to the
emotional and physical needs of this unique population.
As recently as twenty-five years ago, young children
with developmental problems, including SB, faced an
isolated homebound existence or were placed in often
inadequate custodial facilities. A literature review also
reveals that children with SB commonly have language
deficits that often go unrecognized despite average intelligence.11-14 In response, early interventions focusing on
psychosocial and educational models have been emphasized. Failure in independent self-care has been found to be
a hindering factor for employment in young adults with
SB.15 It is therefore of vital interest to understand the factors
leading to this failure in self care, whether they be physical,
emotional, or developmental in origin, and to facilitate
functional transition to adult life.
Issues surrounding transition
Knowledge and communication by paediatricians
A study by Binks et al. outlines several barriers that prevent
successful health care transition from paediatric to adult
medicine for young adults with SB.16 One key point is that it
is often difficult to sever the relationship between the
paediatrician and the patient.16 The paediatrician is seen
often, and builds trust and relationships with the entire
family; this is the nature of paediatric care. Thus, there is a
lack of incentive for all involved to discuss the process of
leaving the paediatric system to transition to adult care.16
This lack of communication inevitably results in a delay of
the transition process until paediatric services are no longer
applicable or available – in Ontario, when the patient turns
19. This is contradictory to the literature, which suggests
that transition should begin as early as possible – by the
ages of 14-16.16
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Training and abilities of adult care providers
The second barrier outlined by Binks addresses the perceived lack of knowledge of adult care providers surrounding the needs of young adults with SB. They may have little
to no exposure to childhood diseases or their sequelae in
adulthood. Young et al. notes that paediatricians are often
concerned that their adult counterparts do not fully understand or appreciate the nature and extent of SB.19 Additionally, Sawyer et al. found that paediatricians specializing in
SB felt that adult care providers did not fully grasp the
needs of this population.17
An ideal approach to transitioning would allow for
several meetings between the paediatrician and future adult
care provider, patient and patient’s family before the
transition begins.18 These meetings would ensure several
things. First, the family physician would receive all relevant
information about the patient from three different sources:
the paediatrician, the family and the patient. They would be
more aware of the patient’s ability to manage their condition, as well as the role the family plays in the patient’s care.
In such a way, the family physician is educated and may
prepare to face the specific challenges of dealing with a
childhood disease progressing into adulthood.

Transition organization – multidisciplinary approach
The ongoing goal is to ensure that quality health services
are available to the patient with SB, given their physical,
mental and emotional needs. Therefore, an organized,
cohesive and coordinated system must be in place during
and after their transition to adult care. Overall health of
youth with SB is reported to be much higher than their adult
counterparts.20 This indicates that adults with SB are not
receiving adequate care. Professionals seen by patients with
SB include nurses, speech therapists, occupational therapists, physical therapists, dentists and many others, but the
variety of care received is much richer for children with SB
than adults.20
Furthermore, in a study by Sawyer et al., several
specific issues with the transition process itself were
highlighted: the time gap between receiving paediatric and
adult care, the sentiment that the adult health care practitioners’ skills were insufficient (especially at the beginning),
and the lack of reassured permanence of their care.17
Coordinated multidisciplinary centers could help to address
these issues.
Studies have outlined different transition programs
which include transition clinics.20 A study by Westwood, et
al. showed that over 90% of children and adults with cystic
fibrosis, another disease in which it is common to transition
from paediatric to adult care, felt that a transition clinic
would be helpful.21 These clinics unite family doctors,
paediatricians, families and patients, and can provide links
to additional resources such as counsellors and psychologists. With the current technology in electronic media that is
available, the feasibility of meetings between multiple
individuals and disciplines becomes possible with conference calling and other internet-based solutions. The scope
of practice may no longer be strictly limited by location, as
these online networks become available to all professional
communities.
The ultimate benefit of such multidisciplinary clinics
or teams would be to all patients with chronic paediatric
conditions, who, thanks to advancing medical technology,
are growing into their adult years.

Interdisciplinary collaboration

We believe there are several components necessary
to facilitate an effective earlier transition. First, it is
essential that the paediatrician must have a realistic
expectation of the duration of their patient’s care, since
their expertise does not always translate to effective
management of adults. It is in the best interest of the patient
for the paediatrician to relinquish the patient’s care.
Second, it is essential that care is taken by the
paediatrician, with help of a multidisciplinary team, to
prepare the child as best as possible for the physical and
emotional challenges of adulthood.17,18 As mentioned, they
include (but are not limited to), sexual health, social
behaviours, alcohol and drug use, body image, mobility,
employment strategies, anxiety and depression. Here, it is
crucial for the information to be tailored to the patient’s age
and stage of mental and physical development, which
highlights the importance of expertise from multiple
disciplines.
Third, it has been shown that young adults with SB
rarely feel comfortable navigating the adult health care
system.16,17 Therefore, they are less able to advocate for
themselves and are hindered in seeking the best possible
care. Often, the paediatrician will continue to care for the
patient.17 This has resulted in poorer health statuses of
young adults with SB as compared to age-matched Canadians, whereas children with SB have the same health status
as their Canadian counterparts.18 This inequality is due in
part to a lack of preparation of the patient by their paediatrician and health care team. Therefore, early in the transition process, the patient must be made aware of the
differences between paediatric and adult medicine, as well
as the structure and function of the adult medical system.

Conclusion
Shunt problems and spinal cord-related symptoms typically
account for a substantial amount of morbidity affecting
young adults with SB and may be avoided if recognized
early in their course. There are, however, also many
important health education, vocational, and psychological
issues that are specific to this age group. The transition from
paediatric to adult care presents a huge challenge to the
health care system itself. It must involve adequate resources
and educated health care professionals to enable these
paediatric patients to take the appropriate steps towards
independence, maturity, and adult fulfillment.
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Introduction
Neuroprostheses are electronic human-computer interfaces
that function to replace or enhance specific aspects of the
central nervous system. There are two main types of
neuroprosthetics currently in use today: motor and sensory.
Technological advances have made possible a wide variety
of prosthetic devices that have greatly enhanced the quality
of life of many patients who have lost sensory or motor
functions.
Sensory neuroprosthetics
There has been a wide interest in neuroprosthetics that
replace primary sensory organs. Perhaps the oldest and
most successful example of a sensory neuroprosthetic is the
cochlear implant. While not a perfect replacement, it has
had a tremendous impact in restoring basic auditory
function to patients. Research is also underway to develop a
visual prosthetic device. However, limitations in current
technology and our understanding of the visual pathway
present roadblocks in the development of an adequate
device.
Seminal work in developing an auditory prosthesis
was conducted by French researchers in 1957, and involved
stimulation of the auditory nerve with a single channel
electrode.1 Even with this simple setup, the patient was able
to distinguish monosyllabic words. More recent technologies informed by our understanding of the auditory system
have dramatically improved this performance. For example,
the portion of the auditory nerve that runs inside the organ
of Corti is tonotopically organized; tones are spatially
arranged by frequency. Cochlear implants take advantage of
this by breaking incoming sound up into multiple frequency
channels. Each channel is fed along its own electrode to the
corresponding portion of the auditory nerve replicating the
natural function of the cochlea. Just four frequency channels
are sufficient to understand speech, which is remarkable
considering that roughly 30,000 hair follicles normally
stimulate the nerve.1
Current implants have up to 22 channels, more than
adequate for understanding speech, but still inadequate for
auditory tasks such as music perception.2 A 2001 study in
Nature demonstrated that improvements in music perception will require improvements in sound encoding.3 Not
only does the auditory system decompose sound by
frequency, it also separates sound into two components: a
slowly varying frequency envelope suitable for speech
recognition, and a rapidly varying fine structure used in
pitch perception and sound localization.
The development of a visual prosthetic has been
much more difficult. Firstly, the amount of visual informa-

tion entering the eyes is more complicated and dense
compared to the auditory system. While four frequency
channels were adequate for functional hearing, having only
four discriminate regions for vision is inconceivable.
Researchers have suggested that a 10x10 array of pixels can
restore just enough vision for navigation and object avoidance,4 while as many as 1000 pixels are need to restore face
recognition and reading.5 The retina is also an incredibly
compact organ with a receptor cell density that cannot be
easily replicated. One group demonstrated that a silicon
microarray for nerve stimulation can be machined with
electrodes that are 0.4mm apart, although this is still a far
cry from the maximal cone density found in the fovea.6
Despite the technological challenges of creating an
artificial replacement retina, it still remains the primary site
of visual prosthetic research for a number of reasons.
Firstly, just as the cochlea is tonotopically organized, the
retina has a natural spatial organization which simplifies
prosthesis design. Secondly, a retinal approach takes
advantage of natural visual processing that begins at that
level, including colour perception and edge accentuation.7
Motor neuroprosthetics
Perhaps the most well known type of motor neuroprosthetic is the artificial cardiac pacemaker. Cardiac pacemakers are devices implanted in the muscular wall of the heart
as a replacement for the sinoatrial node, which is required
to maintain the sinus rhythm of the heart.8 Another
example of an autonomic neuroprosthetic device is the
bladder control prosthesis used in patients with spinal cord
injuries. Although still in the experimental stage, neuroprosthetic devices implanted at various areas of the urinary
tract attempt to replicate the original function of the urinary
tract. Controlled by an external transmitter, the device is
implanted at the sacral anterior root ganglia of the spinal
cord. Signals sent from the device assist in bladder control,
defecation and achieving and sustaining full erections in
male patients.9
In addition to autonomic devices, there are numerous motor prosthetics under development. The neuroprosthetic device showing the most promise for motor control is
an implantable computer chip called the Brain-Computer
Interface (BCI). The BCI can be implanted into the grey
matter of the brain, the skull or outside the skull. The BCI
collects distinct EEG patterns generated by the patient when
they imagine specific movements of paralyzed body parts
and converts them into signals controlling prosthetic
devices.10 The BCI essentially translates the intentions of
the user into movement of the prosthetic device.11 Figure 1
shows an example of a brain-computer interface currently
in clinical trials.
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Figure 1. An example of a brain-computer interface.

11.

Conclusions
12.
In addition to the sensory and motor neuroprosthetics that
have been discussed above, there is a new area of research
focusing on cognitive neuroprosthetics. These devices aim
to restore cognitive function to those who have suffered
brain injury or paralysis due to trauma and those suffering
from Alzheimer’s disease and Parkinson’s disease. Damaged brain tissue can be replaced by integrated circuits,
which would help process information that would normally
be done in the diseased region of the brain. 12
Despite some difficult challenges in designing
neuroprosthetic devices, such as the size of the device,
power source and material interactions with human
physiology, the work done thus far suggests a promising
future .
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Excusing "out of control" behaviour: brain tumour-related aggression
Moska Hamidi (Meds 2013)
Faculty reviewer: Dr. Wallace Liang, Windsor Regional Hospital and Sutts, Strosberg LLP
Everyone gets angry from time to time, and for some people,
anger seems to be the norm, rather than the exception.
However, a relatively sudden shift in character to severe
aggression is not considered ‘normal.’ This kind of aggressive behaviour escalated to an extreme in the case of a 55year old Eastern European immigrant who, in a fit of rage,
beat his wife to near-death with a hammer in 2008.1 Many
similarly unfortunate events occur without attracting the
attention of the medical community. This particular event,
however, did not go unnoticed, as it involved a brain tumor.
The patient has since been incarcerated for his actions, but
could it be possible that the observed and documented
changes in his behaviour were in fact the result of a tumor
or its subsequent treatment? If medicine can provide an
organic cause for his actions, should he be found criminally
responsible for them? To be exact, should he even be
prosecuted for an action he was not legally responsible for?
In order to discuss the moral, medical and legal dilemmas
that arise from such rare and complex cases, the pathogenesis of tumor-mediated aggression and its legal implications
will be further explored.
Case
The patient presented with a one week history of headaches, aphasia and right hemi-paresis. A T1 weighted MRI
and subsequent biopsy of the tumor confirmed a large
glioblastoma (GB) in the left hemisphere, involving the
frontal, temporal and occipital lobes.1 A glioblastoma is a
grade 4 astrocytoma, characterized by high mitotic activity
and necrosis or endothelial proliferation.2 The patient was
subsequently treated for six weeks with concomitant
radiation and chemotherapy. Throughout treatment, the
patients’ family complained of new onset paranoia, despite
no past psychiatric illness. His family denied any aggressive
behavior. In spite of repeated suggestions from his physicians to obtain a psychiatric evaluation, both the patient and
his family refused. Although his motor functions improved
throughout the treatment, to the utter vexation of his family,
his emotional detachment failed to benefit from the shrinking tumor.1 Upon further requests for psychiatric evaluation, the patient discontinued (or withdrew) from treatment
altogether. He was arrested eight months later for savagely
beating his wife, in what can only be presumed to have been
a fit of extreme, unbridled rage.1
Physiology and behaviour
The physiologic functions of the limbic system were
discovered in the first half of the twentieth century.3
Hughlings Jackson had delineated the temporal lobe
(specifically, the amygdala) in the early 19th century as the

origin for anger, aggression and rage.4 Studies demonstrating its role in human emotions were performed in 1963 and
1977, showing that stimulation of the amygdaloid nuclei
induced a strong aggressive response.4 A mechanism of
aggressive behavior production has been demonstrated in
several recent studies on children with epilepsy, which can
be extrapolated to those with tumor-associated seizures.
These children with aggressive behavior and intractable
partial epilepsy demonstrated glucose hypometabolism
(which may be indicative of decreased neuronal activity) in
temporal and prefrontal areas when compared to control
subjects and nonaggressive children with partial epilepsy.5
It is thought that in normal children, these areas suppress
aggression triggered by the activation of limbic structures,
and that loss of function in these areas results in loss of
frontal lobe control.6
It is well documented that tumors of the temporal
lobe can cause seizures.4 Despite the rarity of their occurrence, some of these patients also manifest post-seizure
aggression and other behavioral changes, which may be
associated with the tumor. In documented pediatric cases,
two children (both boys, aged 5 and 13) were found to have
excessively aggressive behavior, which improved upon
surgical resection of their tumors: a meningioma and a
ganglioma, respectively, both in the right temporal lobe.6
The patient in this case had cognitive impairments
that are consistent with lesions in the left frontal, parietal
and temporal lobes. Neuroimaging studies on aggressive
and violent offenders have demonstrated a correlation
between dysfunction of these areas and aggression and
violent behavior. 7
Social and legal implications
Aggression and the gradation of related emotions have
always existed within normal social behavior. It manifests in
early infancy, as children procure from their caretakers the
attention needed to survive.3 While in most cultures rage
and aggressive outbursts are not tolerated, we must, as a
society, consider the etiology of this aggression. The rapid
transition a person can make from a state of reason to one
of uncontrollable anger is rarely appreciated as a possible
manifestation of disease.3 Underlying illness should be
considered when the reaction is grossly disproportionate to
the provoking stimulus or out of character for the patient.
The possibility of a brain lesion leading to acts of extreme
violence, while a rare occurrence, can have tremendous
implications in the legal approach to such cases.
The role of the physician must be established in
treating patients who may potentially harm themselves or
others as a result of their changed behavior. The ruling in
Tarasoff v. Regents of the University of California (1976)
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[N]euroscience will likely have a transformative
effect on the law, despite the fact that existing legal
doctrine can, in principle, accommodate whatever
neuroscience will tell us. New neuroscience will
change the law, not by undermining its current
assumptions, but by transforming people’s moral
intuitions about free will and responsibility.11
The Canadian Criminal Code, Part XX.1, states that “A person
can be found not criminally responsible by reason of mental
disorder.”12 The legal test applied requires that the accused
did not appreciate the nature and quality of the criminal act
or omission or know that it was wrong. Therefore, physicians must be educated and have an enhanced awareness of
the emotional and behavioral ramifications neurological
disease and dysfunction may pose. In fulfilling their duty to
advocate for patient welfare, physicians can promote new
approaches, both medically and legally, to such situations,
and potentially prevent wrongful convictions.
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determined that physicians have an obligation to protect
public safety and can or must breach patient confidentiality
to warn those potentially at risk of impending danger.8 As a
result, patients who are demonstrating signs of aggressive
or violent behavior require careful scrutiny throughout
treatment and beyond, from both health care providers and
family, in order to prevent a tragic outcome.
In addition, the role of medical forensics in the
judicial system is of increasing importance, as science and
medicine are increasingly able to describe biological
influences in the development of criminal behavior. Advancements in neuroimaging, such as CT and fMRI have
afforded scientists the ability to search for organic causes of
aggressive and violent behavior.7,9 In fact, the use of neuroimaging in criminal trials has increased as part of an attempt
to mitigate penalties during sentencing hearings.11 However,
not everyone is convinced of its use in a justice system
based on free will. Some argue that searching for a root
cause in every situation will decrease criminal liability.
However, mitigating factors should not be ignored for the
sake of upholding an unaccommodating penal system. Our
judicial system relies on the principle of fundamental
justice: when personal freedom will be restricted, the State
has the onus to prove intent and act (Mens rea, actus rea). 10
Thus, Greene and Cohen (2004) believe that:
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Profile of Dr. Michael Strong
Gordon Tsang (Meds 2012) and Joyce T. W. Cheung (Meds 2013)

Dr. Michael Strong is the current Director of the London
Motor Neuron Diseases Clinic at the London Health Sciences
Centre and the Arthur J. Hudson Chair in ALS Research.
Commencing July 1st, 2010, Dr. Strong is stepping into the
role of Dean of Medicine & Dentistry.
Dr. Strong is truly one of Southwestern Ontario’s
own, having been raised in Leamington, Ontario. His father,
a microbiologist, worked as the director of the quality
control program for Heinz Canada and then as a teacher at
St. Clair College in Windsor. His mother worked as a nurse.
Both had strong influences on Dr. Strong’s decision to
attend Queen’s University, pursuing a degree in biochemistry, and his eventual enrolment in medical school soon
thereafter. After receiving his M.D., Dr. Strong pursued
training in neurology in London, Ontario, and post-graduate
training at the National Institutes of Health, Maryland,
which he described as “three of the best years of my life.”
“When I initially began my residency training, it was
not with a view towards becoming an academic. I
came to the University of Western Ontario after
receiving my M.D. because I wanted to be a clinical
neurologist and the program offered here was
amongst the best in Canada. I was, however, aware of
the strength in clinical research in dementia at the
time, so this had a role as well in the decision.
Interestingly, the interview process for acceptance
into the neurology training program reflected the
focus of the program on training the next generation
of clinical academics, so it was pretty close as to
whether I would be accepted or not. Not surprisingly
however, given the strengths of the program, I fairly
quickly found that I did have a considerable interest
in the more academic aspects of Neurology. This was
in large part due to the mentorship of Dr. Arthur
Hudson, my predecessor and head of the ALS clinic at
the time.
Following completion of my residency training,
I undertook a three year research fellowship at the
NIH. I wanted to culture motor neurons to see if we
could develop a model of ALS in vitro. Being at the
NIH, we were afforded a great opportunity to
undertake experiments that were high risk, but that,
if successful, could potentially be very high yield. I
was successful in both developing a model of culturing rabbit motor neurons — something not previously done — and in developing a new rabbit model
of ALS.”
Since then, Dr. Strong has won many prestigious awards and
honours including recently being awarded the Sheila Essey
award for ALS research in 2005 from the American Acad-

emy of Neurology and the Forbes Norris award in 2008
from the International ALS/MND Alliance. He is the only
Canadian to have ever won both awards.
With such a strong dedication to and interest in
basic science research in his own career, we asked Dr.
Strong if he would be making any changes to the Schulich
medical curriculum with regards to the balance of clinical
and research components:
“Dean Herbert has left us with a very good educational program at Schulich; I hope to maintain and
build upon that. I am also interested in promoting our
research programs, and moving these to greater
international recognition. When someone talks about
the NIH, for example, there is immediate name
recognition of various labs and research areas. While
this does exist to some degree for Schulich, I would
like to expand this considerably.
Our new president, Amit Chakma, is also very
interested in making UWO known internationally.
The best way to do that is to promote a few areas that
can become renowned globally. Usually, that is
achieved through a combination of strong educational and academic programs. The benefits of such a
direction for Schulich are multiple. We have to
remember that we are living in a time of incredible
scientific advancement, where technologies such as
those embedded in genomics are dramatically
changing not only how we practice medicine, but
what our patients expect of us in terms of scientific
knowledge. So the advantage of educating students
in a milieu of this caliber is that it will help to equip
our students with the skills and the necessary
comfort level to be able to process all the information
that is available, or at least understand how to begin
to interpret it.
It isn’t my intent to push for every student to
become academically focused, but I do want to allow
for those that are to have the opportunities to
develop their interest, much like the experience I was
afforded. Both educational and academic programs
are integrated and necessary, and our goal is to
develop physicians highly interested in both areas.”
Current students are faced with difficult a dilemma – how
much of our time do we invest in clinic and how much in
research, if any. We asked Dr. Strong why he decided to
pursue a clinical career, given his strong research background:
“A large part of it was a personal motivation: my
father had died from cancer and he was treated in
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With such a great balance between clinical work, research,
and a great family life, we had to ask what motivated you to
apply for the Deanship?

Profiles

London, so that experience was ingrained in me. To
be honest, I didn’t like the specialist that was treating
[him], but then again, he couldn’t have done anything
to make me happy considering the situation. My
mother was also a nurse, and I saw her dedication to
the healthcare profession as I grew up.
Another positive influence was my biology
teacher in grade 13, who had a Ph.D. from India. Since
Ph.D.s from foreign countries were not recognized at
the time, he taught biology at my school. He promoted innovative teaching that was ahead of his time.
One of my projects was to work on the brain with a
pathologist at the hospital, looking at different areas
of the brain using routine histological techniques and
trying to see if there was some sort of anatomic
correlate to the different lobes and functions. Pretty
ambitious stuff for a high school student!
It was also during this time that my father
struggled with cancer, and on his hospital bed, he
asked why I wasn’t thinking of going to Queens to
study biochemistry. You have to understand that at
that time, virtually all students in my high school
ended up in either Windsor or London, with a very
few making it as far away as Toronto. Not at all like
today. In hindsight, it was his way of telling me not to
set boundaries for myself. It was also around that
time that I considered going into [the] priesthood,
because I enjoyed working with people. A weekend at
the seminary pretty much clarified where my career
was going to head.”

“I loved my life, so it was not a quest for something
better. One of the reasons is that I do believe our
next generation of physicians has to be very comfortable with balancing life, integrating science, and
being a physician. We have an aging population that
we have to deal with and we need people that are
comfortable with balancing many things because it
will not be easy in a time of tight fiscal resources.
There is a significant research and academic component to our field. It’s a difficult time in research, but
we want to be able to take next generation of
academics and tell them we can survive recessions
and setbacks.
I’ve done a lot of work to address our ability
to do clinical research. We’re in a financial sector that
is constantly squeezed. Our centre is supposed to do
cutting edge research but we’re even struggling to
deliver healthcare. I helped develop the Lifecycle
Research Network (LRN), which is model for doing
clinical research on a large scale across many
different cities in the Southwestern Ontario area. The
next thing to do as Dean is to bring about more push
towards this.”

Your current responsibilities as a clinician-scientist and
administrative leader sound very intimidating. What is a
typical week in your shoes like?
“Each week is highly variable. Key to this however is
my family.
There are various activities that are
seasonal and I try to organize my time around them.
During the summer, I enjoy gardening with my wife,
Wendy, and we play golf, often as a family. When my
kids were younger I would take a week off to either
go camping with them or spend time at a cottage.
Eventually, as the kids became older, I could leave for
a month at a time, and during that we camped all over
Canada and the U.S. I was able to share time with my
children that I will never get again. Better yet, the
hospital didn’t fall down simply because I wasn’t
there. It really was a great time in our lives.
With regards to my average week, I can’t
actually recall having one! It is one of the great
pleasures of being a clinician-scientist in that there
are so many different challenges. I try as much as I
can to get to my lab, so generally start each day at 7
by killing off some paperwork, and then complete the
day doing the same. In between is when I get to the
lab or clinic.”

Dr. Michael Strong

As a scientist, you are always on the cutting edge of new
research. Where do you see your research career heading in
the next 10-15 years, after your tenure as Dean?
“It’s difficult to know if my research career will be
like it is now. If you had asked 10 years ago, I certainly would not have predicted that my lab would be

UWOMJ | 79:2 | Fall 2010
29

Profiles

Profile of Dr. Michael Strong

leading in the areas in which it currently does. The
most difficult challenge for me while a Dean will be
ensuring that I and my lab not only continue to lead,
but that we keep abreast of all of the developments.
If I get to the point in 10 years where I am no longer
doing this, then I will need to seriously consider
whether it might be time to take a step aside and
hand it to the next generation. So, when all is done, I
don’t know if I’ll be back in the lab, but I will be back
doing clinical work.”
Do you have any advice for current medical students on
finding a balance between work and family?
“What you’re establishing here is a life, and your
habits will last a lifetime. Finding ways to enjoy your
life is critical. There is a social side of being a medical
student. There are lots of activities that are already in
place for many of you, so my advice is to keep it up!
You are all self-selected to be physicians. Finding a
balance is a lifelong struggle. You’ll get older, wiser,
have families, kids…and their life becomes a part of
yours. It’s very difficult to balance all of that. We want
you to know that we can provide role models, just as
our previous generation has done.”
For more information about the Lifecycle Research Network, visit http://lawsonresearch.com/clinical_research/
lifecycle_research_network.html.
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Status epilepticus: a neurological emergency
Kalpa Shah (Meds 2012)
Faculty reviewer: Dr. Jorge G. Burneo, Department of Clinical Neurological Science, UWO
Epidemiology
Based on United States data, it is estimated that 6,500 to
15,000 people in Canada each year will have generalized
convulsive status epilepticus (GCSE ),1,2 with a mortality of
20%.3 The incidence of GCSE is highest in the first decade of
life and after age 60.3
Definition
Epidemiological literature defines status epilepticus as a
fixed and persistent seizure lasting at least 30 minutes, 4 the
time interval after which irreversible damage occurs to
neurons. However, clinically it is important to initiate
treatment before 20 minutes and a more practical definition
is: “either continuous seizures lasting at least five minutes
or two or more discrete seizures between which there is
incomplete recovery of consciousness.” 5
Clinical features
Initially, patients with status epilepticus will present with
obvious seizure symptoms, such as tonic, clonic or tonicclonic movements. However, as the condition progresses the
clinical manifestations become subtle and the only signs of
an underlying disorder may be minor twitching or in some
cases no motor activity.6 Electroencephalography (EEG)
monitoring will be required to detect cerebral epileptic
activity. EEG is also useful in distinguishing status epilepticus from pseudoseizures, also known as nonepileptic status.
Pseudoseizures clinically resemble a seizure, but do not
show epileptic activity on EEG and may be precipitated by
suggestions or commands. It is the other main condition in
the differential diagnosis of multiple seizures and is
implicated as the cause about half the time.7
Physiologic changes that occur in GCSE can be
temporally divided into two phases: Phase I (0-30 minutes)
in which compensatory mechanisms are still intact, and
phase II (>30 minutes) when more serious symptoms
develop due to a failure of the compensatory mechanisms.
This classification is clinically useful because the development of phase II symptoms should prompt admission to an
intensive care unit. (See Table 1).
Pathophysiology
The pathophysiology of status epilepticus remains largely
unknown. An insight into the possible mechanism of SE
came from reports of patients who consumed mussels
contaminated with domoic acid, an analogue of the excitatory neurotransmitter glutamate.8 This incident suggests
that excessive activation of excitatory receptors can cause
status epilepticus.

Other evidence demonstrates that status epilepticus
can be caused by substances, such as penicillin, which
antagonize the neurotransmitter GABA.9 GABA is the main
inhibitory neurotransmitter in the brain and so failure of
effective inhibition may lead to prolonged seizures. Ultimately, status epilepticus involves a disorder of the body’s
normal mechanism to terminate a seizure, which can be due
to excessive excitation or lack of inhibition.
Causes - acute and chronic
The causes of status epilepticus can be divided into acute
and chronic. It is important to distinguish between them
since the prognosis, management and response to treatment
differs.
Acute causes of status epilepticus include metabolic
disturbances (e.g. electrolyte imbalances, renal faillure,
sepsis), CNS infection, stroke, head trauma, drug toxicity
and hypoxia. Chronic processes that cause status epilepticus
include preexisting epilepsy, discontinuation of antiepileptic
medication or sub-therapeutic levels of medication, and
seizures due to chronic ethanol abuse. Other processes such
as CNS strokes and tumours can present with status
epilepticus after a latent period of weeks to years.
Cases of status epilepticus due to chronic processes
respond well to anticonvulsant medication. In contrast,
seizures due to acute causes are typically difficult to control
and have a higher mortality.10
Management
The management of status epilepticus includes standard
measures that would be implemented in any medical
emergency, including evaluation of the airway, breathing
and circulation. The next steps in management are to order
blood work and administer glucose, thiamine and antiepileptic drugs.
Relevant investigations to order include: CBC,
electrolytes, calcium, magnesium, liver function, kidney
function, serum levels of antiepileptic drugs, toxicology and
clotting parameters. A lumbar puncture should be performed if infection is suspected.
Furthermore, two IV lines are recommended for
administering glucose, thiamine, anticonvulsant drugs,
normal saline and vasopressors. Thiamine is given to
patients who are malnourished or have a history of alcohol
abuse since they are at risk for Wernicke’s encephalopathy.
Some special considerations in the management of
GCSE are in order:

•

A priority in management is maintaining a patent
airway and adequate ventilation.
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•
•

•

Hyperventilation, tachycardia

Benzodiazepines are fast-acting, potent antiepileptic
drugs, and include diazepam, lorazepam, midazolam, and
clonazepam. Diazepam and lorazepam may both be considered in initial therapy, however lorazepam is preferred
because of its duration of action of 12-24 hours versus
diazepam’s 15-30 minutes duration of action.13 Adverse
effects of IV benzodiazepines include respiratory depression
and hypotension.
Phenytoin is usually administered intravenously
after a benzodiazepine (e.g. lorazepam). Adverse effects
associated with phenytoin are cardiac rhythm disturbances
(incidence of 7%) and hypotension (incidence of 29%). IV
phenytoin may also rarely cause “purple glove syndrome” a
tissue injury caused by venous irritation resulting in
extravasation.
Phenobarbital has a depressant effect on respiratory
drive, level of consciousness and blood pressure. For these
reasons, it is recommended only when benzodiazepine and
phenytoin therapy fails, and administration should ideally
be carried out in an intensive care unit.
Status epilepticus that does not respond to a
benzodiazepine, phenytoin or phenobarbital is considered
refractory and will require therapy with propofol and/or
midalozam.

Lactic acidosis

Out-of-hospital Treatment

Phase II

COMPENSATORY MECHANISMS START FAILING

(> 30
minutes)

Cerebral autoregulation reduced

In situations when IV administration of drugs and monitoring equipment are not available, treatment options include
parenteral or rectal diazepam, sublingual lorazepam and
intramuscular midazolam.

Respiration depressed
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Arterial-blood gas measurements are useful and
often show a metabolic acidosis, which will correct
itself once the seizures stop; sodium bicarbonate
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Introduction
Stiff-person syndrome (SPS) is a rare neurological disorder
involving episodic spasms often preceded by sudden
stimuli, progressive stiffness of the limbs and trunk, and
axial rigidity. Diagnosis of stiff person syndrome can be
elusive due to the fact that patients tend to present with
non-specific muscle complaints of stiffness, spasms and
cramps.1 These symptoms have a large differential diagnosis, including infectious, toxic, neoplastic, vascular, genetic
and autoimmune,2 and often other diagnoses are considered
before stiff-person syndrome. Additionally, the stimuliinduced spasms, social phobia and anxiety experienced by
these patients can expand the differential to include
psychogenic movement disorders.2-4 SPS causes significant
disability and in many cases symptom relief can be achieved
with treatment.1,2,5,6 As such, it is important to recognize
possible cases of SPS and conduct the appropriate tests for
diagnosis. Below is a case report exemplifying an approach
to diagnosis of SPS.
Case report
A 66-year-old woman was admitted to the internal medicine
service after an 18-month history of complaints of worsening stiffness affecting her lower extremities associated with
pain. While the symptoms had started off mild, the patient
rapidly progressed to requiring a walker for safe ambulation.
The patient’s primary caregiver, her son, confirmed this
history. Her son also stated that the patient was extremely
fearful to attempt walking even when the symptoms were
initially mild. The patient denied any symptoms affecting the
trunk or her upper extremities. She denied any tremor, apart
from that which occurred in the lower extremities upon
standing. There were no complaints of autonomic dysfunction. Her speech was normal. By the time she arrived at the
hospital, she was no longer able to ambulate even with a
walker.
Her past history was positive for a history of anxiety,
chronic depression and auditory hallucinations, for which
she was followed by the psychiatry service. Other health
conditions included hypothyroidism, gastroesophageal reflux
(GERD) and osteoporosis. The patient had been treated for
her anxiety and depression with a combination of alprazolam
0.5mg three times daily, citalopram 30 mg daily, and risperidone 0.5 mg daily for approximately one year. Other medications included rabeprazole, residronate, and levothyroxine.
Because of the neuroleptic exposure (risperidone),
the initial thought at admission was that the symptoms
might be secondary to neuroleptic malignant syndrome.
However, the psychiatry service saw the patient in consultation and felt that the lack of autonomic symptoms, focality of

symptoms and lack of delirium argued against such a
diagnosis. The patient did have an MRI of the head and spine
performed which was unremarkable. Concerns were also
raised as to whether or not the patient might be suffering
from drug-induced parkinsonism because of the exposure to
risperidone. The neurology service was subsequently
consulted for a diagnostic opinion.
When examined by the neurology service, the patient
was oriented to time and place, and scored 30/30 on the
MMSE. She was noted to have full extra-ocular eye movements, but her pursuit movements were very saccadic in
nature. The remainder of her cranial nerve examination was
unremarkable. There was no evidence of tremor in the
extremities at rest or with action. She was noted to be mildly
bradykinetic in the upper extremities, but power was fully
preserved. There was mild rigidity in the upper extremities
on passive movement. In the lower extremities, the limbs
were held in rigid extension, such that it was almost impossible to passively move the lower extremities. Her toes
bilaterally were held in continual extension. Her sensory
examination was unremarkable to pinprick, and only
demonstrated elevated vibratory thresholds at the great toes
bilaterally. Her reflexes were 2+ in the upper extremities, 3+
at the knees and absent at the ankles bilaterally. There was
no evidence of ataxia. Her gait could not be assessed.
After reviewing this woman, it was felt that stiffperson Syndrome could be the underlying diagnosis. AntiGAD antibodies were obtained and were positive, supporting
the clinical diagnosis of SPS. The patient was subsequently
started on treatment with diazepam and baclofen achieving a
dose of 15mg four times daily and 25mg three times daily,
respectively. The patient noted a reduction in lower extremity tone and has been able to resume ambulation with a
walker. The mobility in her legs has progressively improved
while her pain has largely resolved with her current medical
treatment.
Discussion
Clinical manifestations
Stiff-person syndrome (SPS) is a rare neurological disorder,
affecting the neuromuscular junction in a progressive
manner, and has a spectrum of clinical presentations.6
Several forms of SPS exist; the most common is classic SPS,
involving auto-antibodies to glutamic acid decarboxylase
(GAD).2,6 SPS, however, is a clinical diagnosis and thus the
presence of GAD+ auto-antibodies is not a requisite for
diagnosis.2,6 The classic form of SPS affects twice as many
women as men and generally presents in the forth to sixth
decades of life.7 The onset is typically insidious, but progressive in nature. In the early stages of GAD+ SPS, patients
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months, followed by a 1-month washout period and
treatment with the alternative agent for 3 months.5 Significant improvements in stiffness and heightened-sensitivity
scores improved for both groups during the IVIg treatment
period.5 Furthermore, a case has been reported describing
significant symptom improvement using rituximab, an antiCD20 antibody that binds mature B cells and targets them
for removal.10 Plasmapheresis is another option available
for treatment of antibody-related SPS.2,6 This allows direct
removal of excess auto-antibodies, however the beneficial
effects are short-term.2,6
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often present with lumbar lordosis and painful muscle
spasms induced by stimuli,2 such as sudden noise, stress or
touch.3,7,8 These spasms can cause falls and patients often
experience fear of crossing the street and open spaces.2 It is
currently unknown if the anxiety and phobias associated
with SPS are caused by the pathogenesis or in response to
the symptoms.2 SPS can become debilitating, with up to 65%
of patients unable to perform routine daily activities due to
symptoms of total-body stiffness, fear of falling and anxietytriggered spasms.5 Depending on the severity of symptoms
or possibly failure of treatment, some patients require
walkers or wheelchairs and may even become bedridden.2,5

Diagnosis
Pathophysiology
In classic SPS, the majority of cases are associated with
auto-antibodies against glutamic acid decarboxylase
(GAD).1,2,6 The GAD enzyme is involved with the synthesis of
the inhibitory neurotransmitter γ-aminobutyric acid
(GABA) from the excitatory neurotransmitter precursor,
glutamate.6 Antibodies against GAD prevent this conversion,
thus dampening the GABAergic inhibitor pathway and
causing accumulation of glutamate.6 It is proposed that the
muscular symptoms of stiffness and spasms result from the
auto-antibodies affecting interneurons in the spinal gray
matter and intracortical inhibitory neurons.6,9
Glutamic acid decarboxylase is most abundantly
present pre-synaptically in the CNS, but is also present in
pancreatic ß cells.2,6 Interestingly, SPS is highly associated
with autoimmune type I diabetes mellitus.2,6 In fact, the
majority of patients diagnosed with SPS either have diabetes or will subsequently develop it.2 While many diabetics
have auto-antibodies against GAD, these auto-antibodies
target a different epitope than in classic SPS and are present
in low titres.2,6,8,9 Thus, the vast majority of diabetics do not
develop SPS.2,9 When considering other autoimmune
disorders in addition to type I diabetes, up to 80% of SPS
patients will be affected by another autoimmune comorbidity.6 SPS responds well to immunotherapy, further
supporting the autoimmune pathogenesis of SPS.2
Treatment
There are two general strategies to treatment of SPS; the
first approach is to treat the neurotransmitter imbalance
directly and the second is to reduce the auto-antibody titres,
treating the imbalance indirectly.9 In the first case, medications such as benzodiazepines and baclofen can be used to
improve GABAergic inhibition.2,6,7,9 The doses of these
medications however are limited by adverse cognitive sideeffects.9 Additionally, monoaminergic inhibitors, such as
clonidine and tizanidine, can also improve symptoms.6
The second approach applies particularly to GAD+
SPS patients due to the autoimmune nature of their
condition. These patient may benefit from immunosuppressive therapy such as steroids and intravenous immunoglobulin (IVIg).2,6 In a randomized, cross-over study, 16
patients were treated with either placebo or IVIg for 3

SPS a very rare disorder, with an estimate of 1:1,250,000
affected.6 Additionally, because its symptoms lead to a
broad differential diagnosis, SPS can easily be mistaken for
other disorders.2 In early stages, patients with SPS often
present with reports of intermittent muscle spasm, but have
a normal neurological exam.2 Additionally, if treated with
diazepam, the EMG findings associated with SPS – continuous low frequency motor activity – are masked, which can
further complicate the diagnosis.2,5,6,8 As the condition
progresses, patients often development phobias and
anxiety.2 This psychological aspect of SPS can lead physicians to look for a psychogenic source for the problem.2-4 As
such, SPS diagnosis can be elusive, but should not be
forgotten in this clinical picture. While diagnosis of SPS can
be made based on clinical findings, auto-antibody titres for
GAD can support the diagnosis.2,6 Thus, although 60-80% of
these patients will have serum anti-GAD antibodies, the
absence of such antibodies does not rule out SPS.1
Conclusion
Stiff-person syndrome is an important diagnosis to consider
when patients present with muscle stiffness, spasms and
cramps.1 Patients with SPS often describe stimulustriggered spasms and falls, and phobia of open spaces,
which may lead clinicians to misdiagnose the condition as
psychogenic movement disorder.2-4 However, it is crucial to
test for this condition as SPS causes significant morbidity
and, in most cases, can be treated to alleviate symptoms.1,2,5,6
Furthermore, SPS can present as a manifestation of an
underlying neoplasm, such as breast cancer, SCLC, lung
adenocarcinoma or mediastinal carcinoma, and may
indicate the presence of or predisposition to diabetes.2
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Introduction: optic nerve anatomy
The optic nerve carries approximately 1.2 million afferent
nerve fibres which originate in the retinal ganglion cells of
the retina.1 Most of these synapse in the lateral geniculate
body, while others are destined for the pre-tectal nuclei in
the midbrain and other centres. The optic nerve is approximately 50 mm long from globe to chiasm and can be divided
into 4 subdivisions.2 First is the intraocular segment, which
is called the optic disc or optic nerve head. Behind the globe
is the intraorbital segment, which is 25-30 mm long. Here
the nerve thickens with the addition of myelin sheaths that
surround the nerve fibres, a function of oligodendroglia.
Interestingly, the optic nerve within the orbit is S-shaped
which allows the eye to move without stretching the nerve.
The nerve will only become stretched if there is severe
proptosis.
After exiting the orbit, the optic nerve enters the
optic canal to be directed upward and inward at a 45-degree
angle towards its chiasmal destination.3 This is called the
intracanalicular segment, and is approximately 6 mm in
length. Last is the intracranial segment, where the two optic
nerves meet at the optic chiasm. Here the optic nerve fibres
from each eye decussate so that each optic tract carries
fibres from the contralateral nasal hemiretina and ipsilateral temporal hemiretina.3
Based on the arterial supply of the optic nerve, it can
alternatively be divided into two segments, anterior and
posterior. The anterior segment is simply the optic disc,
which is supplied by the posterior ciliary arteries.4 There is
also a minor arterial supply by an anastomotic circle called
the circle of Zinn-Haller.5 The posterior segment consists of
the intraorbital, intracanalicular, and intracranial subdivisions and is supplied by a more complex system of peripheral (centripetal) and axial (centrifugal) vessels.5,6 Venous
drainage of the optic nerve occurs almost exclusively via the
central retinal vein.

In this test a series of colour plates are used to determine
colour recognition in each eye. Loss of signal transmission
from cone receptors that are concentrated in the macula
through the optic nerve is indicative of optic nerve dysfunction. There can be a marked difference in colour recognition
between eyes if there is unilateral optic nerve damage. One
should consider that approximately 5% of males have some
degree of red-green colour blindness while performing this
test.3
Visual fields
The simple screening examination is confrontation visual
field testing. The examiner stands approximately 1 metre
from the patient with each person covering one eye and
looking straight ahead. A target finger is moved centrally
until seen by the patient and this is repeated in several
quadrants. A counting fingers test may be more reliable and
automated machine testing is the most sensitive means of
detection.
Swinging flashlight test
This is one of the most valuable tests of optic nerve dysfunction available for the general physician. The abnormality
detected is a Relative Afferent Pupillary Defect (RAPD), also
known as a Marcus Gunn pupil. The key concept is that the
optic nerve is responsible for the afferent limb of the
pupillary reflex. In a dim room, light shone on a normal eye
will result in consensual and contralateral pupillary
constriction. The flashlight is then quickly moved to shine
on the other eye and if there is optic nerve dysfunction in
that eye then both pupils will abnormally dilate.
Optic nerve disorders
Ischemic Optic Neuropathy (ION)

Examination
Disorders of the optic nerve affect the main components of
vision which are contrast, brightness and colour.3 There are
four main tests used to evaluate these components and
ultimately optic nerve function.
Visual acuity
This is performed with the aid of a Snellen chart, as the
patient reads the smallest line of identifiable letters from a
distance of 20 feet (6 metres).
Colour plates

ION is the most common acute optic neuropathy in patients
over 50.5,7 As the name implies it is caused by optic nerve
ischemia, and patients classically present with abrupt onset
of painless, unilateral visual loss. It can be subdivided into
anterior ION (AION) vs. posterior ION (PION) based on the
location of the ischemia, or arteritic vs. non-arteritic based
on the etiology of the ischemia.
Arteritic AION is caused by systemic vasculitis that
affects the optic disc, most commonly from temporal
arteritis (TA). Prompt diagnosis and treatment are imperative as TA can be lead to blindness or death. Headache,
often severe, is the most common symptom associated with
TA, occurring in approximately 50% of cases.8 Other
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Optic Neuritis

Arteritic ION

Non-Arteritic ION

Acute Glaucoma

Open-angle
Glaucoma

Age

<50

>55

50-70

Mean 60

>65 increases with
age

Symptoms

Pain, colour vision
impaired greatly
in affected eye

Possible
Symptoms of TA +
decreased colour
vision

Decreased colour
vision

Nausea and
vomiting, pain,
coloured haloes
around light

Painless, visual
field contraction
noticed late

Signs

RAPD

RAPD

RAPD

Fixed middilated pupil, red
eye, hazy cornea,
ciliary flush

Cupping of disc

Visual Loss

Progressive, hours
to days

Sudden and
profound

Sudden, often on
awakening

Profound, within
hours

Gradual, over many
years

Visual Field Loss

Diffuse
depression,
central scotoma

Altitudinal

Altitudinal

Scotomas, gradual
peripheral loss

Optic Disc
Appearance

1/3 patients have
mild swelling
(Normal if
Retrobulbar)

Swelling and
chalky/white
appearance
(Normal if PION)

Swelling with
associated
hemorrhages

Cup:Disc ratio >0.5,
or >0.2 difference
between eyes

Table 1. Clinical summary of common optic nerve disorders.

classical symptoms include jaw claudication, scalp tenderness, anorexia, weight loss, anemia, fever and visual loss.5
Elevated inflammatory markers – C-reactive protein (CRP)
and erythrocyte sedimentation rate (ESR) – strongly suggest
the diagnosis, but temporal artery biopsy remains the gold
standard and is recommended in all suspected cases. The
hemoglobin level should always be considered when
reviewing the ESR as anemia may mask an elevated ESR.
CRP, on the other hand, is not affected by hematologic
factors or age.5 Treatment of TA is with high dose corticosteroids. The vision loss is often more severe than its nonarteritic counterpart, as 75% of patients with arteritic AION
demonstrate visual acuity of 20/200 or worse.5 Transient
visual loss, called amaurosis fugax precedes the profound
visual loss in up to 30% of cases.5
Non-arteritic AION is the most common form of ION.
Caucasians account for 95% of cases,9 and individuals
typically present in their 60’s.10 The exact pathogenesis is
unknown. It is a presumed diagnosis that is made when TA
is ruled out. Visual loss may be less profound and partial
field loss is common. Contrary to what one might assume it
is not triggered by an embolic event as in ischemic stoke.6
There is no proven treatment for non-arteritic AION.
Metabolic issues such as diabetic control and hypertension
should be considered and treated appropriately.
PION is defined as infarction of the retrobulbar
portion of the optic nerve, and accounts for only 10% of
cases of ION.7 It is characterized by a normal appearing

optic disc that later becomes atrophic.11 TA is the most
common cause of PION. It is very important to rule out TA
in all older patients who present with an afferent pupillary
defect or unexplained visual field defect.
Optic neuritis (ON)
ON is characterized by inflammation of the optic nerve. It
must be thought of in cases of visual loss in younger
patients. Clinical features of ON include visual loss, RAPD,
optic disc edema and a classic central scotoma.12 Most
patients improve without treatment, however intravenous
steroids may hasten recovery and may reduce the risk of
developing multiple sclerosis (MS).13 An MRI should be done
to ascertain the long term risk of developing MS as multiple
white matter lesions on an MRI increases the risk of
developing MS to over 50%.14,15
Glaucoma
Glaucoma is a disease that causes nerve fibre layer loss
within the intraocular portion of the optic nerve. Cupping of
the disc is apparent before the disc becomes pale. The exact
mechanism of glaucoma is not fully understood, but it is
highly associated with elevated intraocular pressure (IOP).
There are two types of glaucoma, open-angle and closedangle.
Open-angle glaucoma is a chronic condition account-
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ing for the majority of cases. Patients have chronically
elevated IOP due to impaired drainage of aqueous humour
from trabecular meshwork dysfunction. Visual loss is
gradual and is characterized by peripheral visual field
contraction and scotomas (blind spots). Generally the
patient does not notice the visual field loss until late, which
is why screening, especially in those with risk factors is
important. Risk factors include increasing age, family
history, African-American race and IOP above 22 mm Hg.1
Treatment is commonly with medications that either
decrease aqueous production or increase drainage, and
less commonly with surgery.
Angle-closure glaucoma, also known as acute
glaucoma, is a medical emergency. It is most often caused
by pupillary block between the iris and lens which then
bows the iris forward blocking the angle and aqueous
drainage through the trabecular meshwork. Complete
vision loss can occur within hours. Patients typically
present with a red and painful eye, nausea and vomiting,
and they see coloured haloes around lights.1 Examination
reveals a fixed, mid-dilated pupil, hazy cornea and firm
globe.1 The iris is mid-dilated because this is where it can
be in greatest contact with the lens to cause pupillary
blockage and as the pressure rises, it becomes ischemic
and remains mid-dilated. Immediate medical treatment
with topical pupillary constrictors, intravenous osmotic
agents and oral carbonic anhydrase inhibitors is required,
followed by a laser iridotomy to allow the aqueous to
bypass the pupillary blockage.

Examination of the optic nerve and understanding its
disorders are of great importance to the general physician,
as misdiagnosis of optic nerve pathology can lead to
permanent visual loss. Table 1 summarizes important
differences between the optic nerve disorders that one will
encounter as a general physician.
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Faculty reviewer: Dr. Lorne Parnes, Department of Otolaryngology, UWO
Joseph Babinski is famous for his 1896 description of the
Babinski sign, an abnormal plantar reflex associated with
dysfunction of the pyramidal system. He is less well-known
for his “other” Babinski sign: paradoxical raising of the
eyebrow associated with closure of the eye, a feature typical
of hemifacial spasm.
As Babinksi noted in 1905, hemifacial spasm (HFS) is
a disorder of painless, involuntary facial twitches confined
to the muscles supplied by the facial nerve. While benign, it
causes significant morbidity due to excessive closure of one
eye, and the social effects of an abnormal appearance.1
Unfortunately, facial twitches are often attributed to stress
or anxiety, leading to a delay in diagnosis.2 A vigilant search
for organic causes is essential when these symptoms arise,
as highly efficacious treatment options for HFS are available
and can significantly improve quality of life.
HFS occurs more commonly in females (2:1) and has
an overall prevalence of approximately 10/100,000. 1 The
orbicularis oculi is the site of onset in the large majority of
cases.3 Over months to years, the disease spreads to other
muscles. 2 Spasms are described as clonic or tonic, are
aggravated by stress, fatigue and anxiety, and persist during
sleep.2 Disease is usually unilateral, and spasms are synchronous in all affected ipsilateral muscles. 2 Bilateral
disease occurs in a small minority of cases, and spasms are
never synchronous bilaterally.2
In most cases, hemifacial spasm is due to arterial
compression of the root exit zone (REZ) of the facial nerve.
This is similar to the proposed mechanism of trigeminal
neuralgia, in which the trigeminal nerve is compressed in
the REZ, causing demyelination and recurrent episodes of
intense pain.6 In much the same way, compression of the
facial nerve causes spontaneous irregular discharges,
leading to involuntary muscle contractions. As well, nonsynaptic neural transmission (ephapsis) between branches
of CN VII may occur, causing synkinesis.7
Most commonly, the aberrant artery is the posterioinferior cerebellar artery (PICA), the antero-inferior
cerebellar artery (AICA), or the vertebro-basilar artery (VB).
In one series, these vessels were responsible 61%, 56% and
27% of the time, respectively.8 The same study found that
multiple vessels were responsible 40% of the time.8
However, up to 25% of the population has vascular loops
compressing CN VII, suggesting that this alone is insufficient
to produce HFS.9 Vascular loop decompression surgery via
the posterior cranial fossa is very effective in providing
relief from spasms. For some patients, relief is almost
immediate, while for others it can take up to a year following surgery to see the full effects. This delayed cure suggests that HFS is not only due to mechanical compression.
Demyelination of the nerve from the brainstem and hyperexcitability of the facial nerve nucleus due to irritation from

neurovascular compression may play a role. The slow
reversal of these plastic changes explains the delay.8
Several other diagnoses can present in a similar
fashion, including benign essential blepharospasm (BEB),
focal motor seizures, and craniofacial tremor. These are
differentiated largely based on clinical presentation, so a
careful history and physical exam are essential. For example, BEB often presents with spasms of the orbicularis oculi
and adjacent muscles, which may be difficult to distinguish
from HFS. However, BEB is often associated with eye
irritation, vague ocular pain and photopobia.4 If the facial
spasms are associated with body tremor, or a family history,
craniofacial tremor is more likely.5 Focal motor seizures are
implicated when post-ictal weakness and a greater involvement of the lower face are present.5 If the clinical presentation is ambiguous, electrophysiologic studies and imaging
can aid in the diagnosis.
The characteristic sign of HFS on electrophysoiologic
studies is a response in distant facial nerve branches
following a stimulus to a single branch. This can be seen, for
example, by spread of the blink reflex on stimulation of the
supraorbital nerve to muscles other than orbicularis oculi.
This is referred to as lateral spread response (LSR) and is
attributed to spread of excitation at the site of ephapsis.11
Rarely, HFS is caused by tumors, arteriovenous
malformations, and venous compression.10 Because the risk
of tumor is low, imaging may not be cost effective when the
diagnosis is clear.2 However, a careful neurologic exam for
focal signs is essential, and imaging is suggested if these are
present or if conservative management fails. 2 Advanced
MRI techniques, such as constructive interference in steady
state, are effective at identifying neurovascular contact.2
Imaging may also assist in surgical planning.2
While spontaneous remission of symptoms is
possible, it occurs in less than 10% of patients,2 and significant effects on quality of life usually demand intervention.
Several oral medications have been studied, including
carbamazepine, anticholinergics, baclofen, clonazepam and
haloperidol. However, sample sizes have been small and it is
difficult to confidently interpret the results.2 The effects of
oral medications are usually transient,2 and unacceptable
side effects often occur.1 For many patients, this is not a
viable treatment option.
In contrast, many physicians consider botulism toxin
(BTX) to be the treatment of choice.2 While few double-blind
randomized studies evaluating BTX for HFS exist,1 the
available evidence is encouraging. Park et al described an
open-label study of 101 HFS patients, 98.6% of which had
excellent results after injection of botulism-A. The mean
duration of effect was 16.5 weeks, with a range of 11-40
weeks.12 In a review of the HFS-BTX literature, Jost et al
found a total of 37 open case-control studies (N=2295) in
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assessed became spasm free only after a significant interval
(4 to 12 months). Since delayed effects of MVD are common,
he argued, final assessment of outcome should not be made
until 1 year post-operative.8 Neves et al noted that, in
addition to delayed success, HFS can also recur after an
MVD that was successful in terms of LSR disappearance.
They found that intraoperative LSR changes did not correlate with HFS relief on the first post-operative day.7 However, they did find a correlation between absence of LSR at
the end of surgery and the long-term efficacy of the MVD.7
Whether elimination of LSR at the time of surgery predicts a
good clinical outcome remains unclear.4
Involuntary facial movements are often attributed to
stress and disregarded. An awareness of HFS and its
presentation is essential, as HFS can result in severe social
and functional disability4 and highly efficacious treatment
options exist. However, the benign nature of this disorder
requires that these treatment options be carefully weighed.
No treatment is without risk, but MVD in particular is an
invasive solution that carries a risk of significant disability.
A careful risk-benefit analysis must be undertaken in order
to balance the potential of symptom relief with the risks of
therapy.
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which good to excellent results were reported in 76-100%
of patients.13 Adverse effects include facial droop, ptosis,
diplopia, lid edema and ecchymosis,12 with facial weakness
being the most common.1
Microvascular decompression (MVD) of the facial
nerve is the only truly curative option. It involves freeing
the nerve from the compressing vessel(s) at the cerebellopontine angle. The offending vessel is gently mobilized away
from the facial nerve and a small, rectangular piece of Teflon
sponge is then interposed between the REZ on one side and
the aberrant vessel(s) on the other.8
While MVD has a high success rate (> 90% in some
series), the recurrence rate remains up to 20%.2 Furthermore, the potential risks are significant, including facial
nerve dysfunction, lower cranial nerve dysfunction, intracranial infections, cerebrospinal fluid leaks, and temporary
or permanent damage to CN VIII.2 According to some
reports, 7-26% of patients will suffer a degree of temporary
or permanent hearing loss.2 A large study of 668 patients by
Park et al found that 2.2% of patients experienced permanent hearing loss, with 0.7% of these suffering total deafness.14
According to several studies, monitoring of brainstem auditory evoked potentials (BAEP) reduces the risk of
hearing loss complications.8 BAEP monitoring allows
surgeons to watch for the increased latency of peak V and
decreased amplitude of peak I, which are the early warning
signs of excessive stretching of the cochlear nerve and
impairment of the cochlear vascular supply, respectively.8
This allows dangerous maneuvers to be stopped or corrected, and appears to significantly reduce the risk of postoperative hearing loss.8
Intraoperative monitoring of lateral spread response
(LSR) is more controversial. The goal is to see disappearance of the LSR when the aberrant vessel is moved away
from the facial nerve.4 This can augment surgical decisionmaking, and some authors suggest that it leads to improved
outcomes.15 In 1987, Moller and Jannetta advocated routine
intraoperative monitoring of LSR, contending that this
would ensure adequate decompression. If LSR was observed
at the end of the procedure, they reasoned, symptoms were
likely to persist.8 Therefore, if the LSR does not disappear
following decompression of the most obvious site, a search
for a second site can be undertaken.7 In a study by Mooij et
al, a second compression site was found in the majority of
these cases.16 Several other authors advocate for LSR
monitoring during MVD, including Sekula et al, who found
that the probability of cure was 4.2 times greater if LSR was
abolished during surgery than if it persisted.15
Conversely, a number of studies have questioned the
value of LSR monitoring. Joo et al examined 32 patients who
had continuing LSR after MVD. Of these, 21 did not display
HFS at 1-week follow-up. The authors argued that demyelination of the REZ may lead to a delay in normalization of
electrophysiologic muscle responses, even when decompression is effective.17 Similarly, Sindou examined outcomes
in the longer term and found good results even in patients
with persistent LSR at the end of MVD.8 One third of patients
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Introduction
Epilepsy is a chronic neurologic disorder characterized by
recurrent, unpredictable seizures.1 It is estimated to affect
0.5 – 1% of the world’s population.2 Epilepsy is not a
singular condition, but instead a diverse family of disorders
with many causes, all of which indicate underlying brain
dysfunction.1 This heterogeneity has important implications
with respect to treatment regimens and patient responsiveness. About 35% of patients with epilepsy are refractory to
anti-epileptic drugs, and of that group, only a quarter may
benefit from resective brain surgery.3 Deep brain stimulation (DBS) may be a suitable treatment alternative for
medically refractory patients who are not candidates for
conventional surgical resection.
Procedure
DBS is a neurosurgical technique that uses electrical
impulses to modulate or interrupt the inherent electrical
activity of deep brain structures. Functional neurosurgeons
use stereotactic MRI or CT scans to create a 3D coordinate
system, allowing them to precisely locate anatomical targets
and map out a suitable trajectory for reaching these targets.4
An electrode (lead) is implanted in the intended deep brain
structure, and a battery-powered implantable pulse
generator (IPG) is embedded in a subcutaneous pocket
positioned inferior to the clavicle. An insulated extension
wire that runs up the neck connects the two devices. The
IPG is programmed to relay electric current to the lead,
which then stimulates the targeted deep brain areas.5
Since acquiring FDA approval for the treatment of
essential tremor and Parkinson’s disease in 1997,6 DBS has
been used for dystonia,7 and has shown promise in the
management of Tourette’s syndrome, obsessive-compulsive
disorder, and treatment-resistant depression.8,9 The success
of DBS in treating movement disorders has prompted
interest in the potential for DBS as a treatment alternative
for medically refractory epilepsy.
Deep brain targets
A brief summary of selected deep brain targets that have
been under investigation in animal and human models is
presented here.
The substantia nigra pars reticulata (SNR) is known
to be an important anticonvulsant site in rats. Pharmacologic animal studies have implicated the SNR as part of a
‘nigral control’ system for epileptic seizures.10 Since then,
DBS of the SNR has resulted in seizure suppression in
animal models, though no human trials have been published
to date.11

The subthalamic nucleus (STN) directly innervates
the SNR, thus providing a rationale for using stimulation to
interfere with this neural circuit and disrupt epileptogenesis.12 Small human trials have demonstrated at least 50%
overall seizure reduction using STN DBS.13-15 Further studies
are needed to clearly establish its clinical efficacy and to
determine whether the optimal stimulation target is the
STN or the SNR itself.3
Temporal lobe epilepsy is common in adults and
frequently does not respond to medical therapy.2 While
temporal lobectomy is an effective treatment for certain
patients, surgical resection is less desirable for patients
whose seizures involve bilateral foci and who may suffer
memory issues as a result of the operation. An alternative
treatment, hippocampal stimulation, has been shown to be
effective at reducing seizure frequency in patients with
mesial temporal lobe epilepsy (MTLE).16,17 A double-blinded,
randomized controlled study demonstrated a 15% median
seizure reduction in four medically refractory MTLE
patients for whom temporal lobe resection was contraindicated. No adverse effects were reported, and one patient
had a substantial long-term benefit.16 Another doubleblinded trial assessing hippocampal stimulation reported a
50-95% seizure reduction in certain refractory MTLE
patients. It is worthwhile to note that this stimulation did
not result in memory deterioration.17
Stimulation of two thalamic structures, the centromedian nucleus (CM) and the anterior nucleus of the
thalamus (AN), has provided encouraging results in human
trials. The CM is involved in modulating cerebral cortex
excitability, and its location between cortical, limbic and
basal ganglia structures makes it an attractive target for
disrupting epileptic neural circuits. Recent human trials
using CM DBS have reduced seizure frequency by 80-95 %
in certain forms of epilepsy.18,19
The AN’s anatomical connections suggest its potential as a vital target in the control of limbic epilepsy.11
Several animal studies have confirmed the AN’s role in
seizure propagation,20-22 and recent human trials have
reported seizure frequency reduction using AN DBS.23-25 Of
considerable interest is the recently published Stimulation
of the Anterior Nucleus of the Thalamus in Epilepsy
(SANTE) trial: a controlled, randomized, double-blinded
trial that examined data from 110 patients in 17 U.S. centres
who received bilateral stimulation of the anterior thalamic
nuclei. During the first 3 months (double-blinded phase),
half the patients received active stimulation and half did not.
Those that received stimulation had a median decline in
seizure frequency of 40.4%, compared to 14.5% for the
control group. Then all patients received unblinded stimulation for the remainder of the trial. After a two year followup, 54% of patients had their seizures reduced by at least
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half, with 14 patients being seizure-free for at least 6
months.26
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Complications
DBS is an advanced neurosurgical procedure. The accuracy
required and complexity involved makes it prone to
complications. Adverse events can be categorized according
to those arising from the operation, the implanted hardware, or the electrical stimulation.27
The most severe operation-related complication is
intracranial hemorrhage. While the risk from implanting a
single lead is low, sometimes multiple passages are required
to ensure proper electrode placement, increasing the risk of
symptomatic hemorrhage. With an average distance of 8cm
from the cortical surface to most deep brain targets, utmost
care must be taken to avoid major cortical blood vessels.
Advances in imaging techniques, combined with thorough
surgical planning, should help to ensure accurate lead
placement with a minimal number of passages.27
Anchoring the electrode to the skull too tightly may
fracture the device, causing a short circuit and draining the
IPG battery. On the other hand, constant head and neck
motions create traction that may cause a loosely attached
electrode to migrate from its desired target. Infections
around the anchorage site, the IPG site or the extension
region may also complicate the procedure and necessitate
removal of the entire system. Antiseptic cleaning procedures and prophylactic antibiotics may be used to curb this
risk.27
Stimulation-related complications include confusion,
depression, and mood changes. These may arise from
malposition of the electrode. Indeed, many of the deep brain
targets are very small, and a misplaced lead, even by a few
millimetres, may cause unwanted side effects. However,
these events are mostly reversible and adjustable, and no
major stimulation-related events have been reported thus
far.28

tion parameters for using DBS to treat epilepsy have largely
followed those for movement disorders; however, the
optimal protocol of DBS for epilepsy has yet to be determined.11
An alternate strategy, called ‘closed-loop stimulation,’ uses real-time seizure detection algorithms designed
to interpret characteristic EEG cues representing the onset
of epileptiform activity, and deliver electrical stimulation
accordingly. There is growing evidence that this type of
adaptive stimulation may be effective in humans.31,32 The
development of reliable automated detectors will be
required to ensure this method’s feasibility.
Future directions
The success of DBS in treating motor disorders, along with
its expanding potential in the management of numerous
other conditions, including epilepsy, has “brought functional
neurosurgery back to an exciting era.”27 To firmly establish
the role of DBS for epilepsy, optimal stimulation parameters
and deep brain targets must be defined for the various
seizure types and syndromes. A better understanding of the
mechanisms by which seizures propagate and how electrical stimulation has its effect will help to identify ideal
surgical candidates and provide them with another therapeutic option worthy of consideration.
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We sleep less than ever before.1 Occupational stress, familial
commitments and an increasing number of distractions
make it difficult for us to get the traditional eight hours of
sleep. Many success stories about people sleeping only a few
hours a day pressure us to think that we need to sleep less
in order to be successful. Consequently, sleep deprivation
has become such a common phenomenon that some people
do not even realize their exhaustion. However, demanding
schedules for doctors persist and trainees are forced to
learn to sleep less. Apparently, the sleep quality and
satisfaction among medical students and residents is
relatively low, and many of them try to compensate for their
lack of sleep by taking caffeine pills or coffee.2 Is sleep really
something we should strive to cut back on? What are the
consequences of frequent sleep deprivation on our ability to
learn? In the following paper, we will look at the present
knowledge of the role of sleep in memory consolidation.
What is sleep? Although often perceived as a passive
and inactive period, there are many physiological and
neurological changes occurring during sleep. Sleep can be
divided into rapid eye movement (REM) sleep and non
rapid eye movement (NREM) sleep. The latter can be further
divided into light sleep (stages 1 and 2) and slow wave sleep
(SWS, stages 3 and 4). Sleep gets progressively deeper from
stages 1 to 4. Each sleep cycle proceeds from lighter sleep to
SWS and then to REM, and this SWS to REM cycle is repeated several times throughout the night. The first half of
the sleep is predominantly SWS, whereas the last half of the
sleep is predominantly REM.3
One of the most exciting and ongoing debates in the
field of sleep research is whether or not sleep contributes to
memory and if it does, how so? Memories are initially
"encoded" when the brain engages in novel experience and
action. These memories, however, require consolidation,
which consists of stabilization and enhancement.3 A large
number of studies offer a substantive body of evidence
supporting the role of sleep in what is known as sleepdependent memory processing.
Evidence of sleepdependent memory has been found in many species,
including humans and non-human primates, cats, rats, and
mice using a variety of behavioural paradigms.4 These
studies offer mixed conclusions about the role of sleep in
simple, emotion-free declarative memories. For example, a
recent study has shown that facial recognition memory was
unaffected by subjects deprived of sleep for 35 hours.5
However, other studies indicate that both SWS and REM
sleep contribute to consolidation of complex, emotionally
salient declarative memories. For instance, even though the

aforementioned sleep-deprived subjects remembered
familiar faces, they had much more difficulty remembering
in which of the two sets of photos the faces had appeared.5
In other words, their memory for the context of the faces
was significantly decreased. It is interesting to note that
while large doses of caffeine reduced the feelings of sleepiness and improved the ability of the sleep-deprived subjects
to remember in which set the faces had appeared, the level
of recall was still significantly below the level of the nonsleep-deprived subjects.5
There is little doubt that sleep plays a critical role in
post-training consolidation of procedural or skill memory.4 Recent studies have shown that memory stabilization
largely occurs during wakefulness, whereas memory
enhancement occurs primarily, if not exclusively, during
sleep; through this enhancement either previously lost
memories are restored or additional learning is produced,
both without the need for any further practice.4 Thus,
through sleep, the enhancement phase of memory consolidation causes the active retention of memory instead of its
decay.
The enhancement phase occurs during slow wave sleep
SWS is most prominent during early sleep. It is characterized by the appearance of slow oscillations, spindles and
sharp wave-ripple field potential oscillations on an electroencephalogram (EEG).3 These various types of wave
activities originate in different centres of the brain and are
thought to play a role in memory consolidation. In the
hippocampal-neocortical model of memory consolidation, it
is proposed that the active memory accumulated during
wakefulness is stored as fragments predominantly in the
hippocampus as well as in neocortical regions.6 Studies have
shown that by utilizing transcranial direct current stimulation, one can artificially induce increased SWS and enhanced
hippocampal-dependent declarative memory consolidation.7 It is hypothesized that during periods of SWS, slow
oscillations originating from the neocortex repeatedly
stimulate the newly stored information in the hippocampus
and cause their reactivation.6 This reactivation is associated
with the presence of sharp wave-ripple activity as well as
spindle activity.8 The sharp wave-ripple activity originates
from the hippocampus, while the spindle activity originates
from the reticular nucleus of the thalamus, which travels to
the entire neocortex via the thalamocortical circuitry.8 The
process of reactivation essentially allows recently stored
memories in the hippocampus to help educate more
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permanent stores within the neocortex. This is mediated by
spindle activity, which causes changes in calcium permeability of pyramidal neurons (important neocortical neurons in
the relay of input into the neocortex).3 Varying calcium
levels have been shown to play a role in the expression of
genes that affect long-term plastic changes associated with
memory formation and maintenance.9
In addition to memory consolidation, SWS has also
been shown to aid in the encoding and formation of new
memory in the subsequent wakefulness period.10 It has been
well characterized that neuronal synapses possess great
plasticity and can alternate between long-term potentiation
(LTP) and depression.3 Calcium influx and delivery of
specific receptors to the excitatory synapses facilitate these
changes.11,12 The delivery of excitatory receptors to the
synapses increases the synaptic strength and LTP, and this
process is found to be more prominent during wakefulness
in rats.11 This indicates that strong synaptic circuits cannot
be maintained indefinitely due to limitations on energy,
space, and saturation.11 Hence, the down-regulation of these
receptors observed in SWS may be crucial for the homeostasis of neuronal plasticity. However, this does not mean that
sleep is devoid of LTP activities, and it is hypothesized that
this process occurs during REM sleep. Animal studies have
shown that exposure to a novel environment during
wakefulness is associated with increased expression of
immediate early genes during sleep.13 They in turn activate
several receptors, which induce LTP. The process of
"transferring" memory from its temporary hippocampal
storage sites to its more permanent neocortical sites has
also been suggested to play a role in priming hippocampal
structures for the formation of new memories.14 fMRI
imaging studies support this hypothesis by showing
significant reduction in hippocampal activity following sleep
deprivation during memory encoding activity compared to
controls.14 Furthermore, recent studies evaluating the effect
of SWS on the acquisition of temporal memory (memory of
when events occur) showed a significant deficiency in

temporal memory recall in the sleep deprived group
compared to controls.15 This experiment controlled for
confounding variables such as stress from the lack of sleep
by allowing a 36 hour sleep ‘rejuvenation’ period for both
groups. Furthermore, it has been shown that even a nap of
significant duration, containing SWS, shows significant
correlation with enhanced declarative memory.16 Moreover,
physiological and behavior studies have shown the importance of SWS on the consolidation of new and old memories
and thus can be thought to play an integral role in the
effective acquisition and storage of new information.
The role of rapid eye movement sleep
REM sleep represents the late stage of the sleep cycle. It is
characterized by reduced muscle tone and fast, low-voltage
EEG waves.17 Early behavioural studies led to the development of the hypothesis that REM sleep is involved in
memory consolidation.18 Following a period of intense
learning, it has been shown that there is an increase in REM
density and the number of rapid eye movements.19 Furthermore, altering the levels of REM during sleep may affect
memory acquisition. Donepezil, an acetylcholinesterase
inhibitor used for treatment in Alzheimer's, induces an
increase in REM sleep. This increase is linked to an enhancement of memory performance.20 In contrast, a decrease in
REM sleep inhibits learning, as seen in REM deprivation
studies in both animals and humans. Physiologically, the
discharge patterns in the hippocampus during training on a
circular track task (a common experimental setup to test for
spatial recognition memory) are also mimicked during REM
sleep, which suggests that the learned task is replayed while
asleep.21 The increase in the amount of REM sleep postlearning, change in memory performance by altering the
amount of REM sleep. and evidence of learning during REM
sleep provide support for the aforementioned hypothesis.
Recently the role of REM in memory consolidation
has been called into question. The REM depression studies
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have been criticized for the use of the "platform-technique,"
where an animal is placed on a small platform surrounded
by water. As the animal enters the REM stage of the sleep
cycle, its muscles relax causing it to fall in and thereby
disrupting that stage of sleep. This technique produces a
high level of stress in the animal, resulting in confounding
factors such as hyperactivity, anxiety and irritability.
Furthermore, depressed patients treated with monoamine
oxidase inhibitors, which block REM sleep, do not show
memory impairments.22 The inconsistent results with
respect to the REM sleep-memory consolidation hypothesis
have led to a debate in the field, with some suggesting that
REM sleep is only important for procedural memory.

11.

12.

13.

14.

15.
Conclusion
Despite the controversial role of REM sleep in memory
consolidation, there is no doubt that sleep has a profound
influence on how we learn. Medical students are constantly
torn between the need to stay up and learn those extra few
pages, and getting the sleep required. However, many
studies have shown a decrease in memory acquisition and
consolidation with a lack of sleep. Although staying up late
may help students get the few extra points needed to pass a
course, it will hinder the ability to retain what has been
learned. Future doctors must optimize learning habits today
to take better care of patients tomorrow.
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